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Abstract
Antipsychotic medication use (APU) in assisted living and residential care (AL/RC)
settings is an under-studied and controversial health policy issue. APU in older adults
with dementia is associated with an increased risk of falls, hospitalizations, and early
mortality. I operationalize the Institutional Analysis and Development Framework using
a situational analysis approach, an extension of grounded theory methods, to explore the
APU in Oregon AL/RC settings. Regulatory deficiency citations, Oregon AL/RC
population data, and semi-structured interviews suggest that staff role clarity,
organizational characteristics, and perceived agency influence decision-making around
APU. AL/RC providers and caregivers are forced to simultaneously balance and
prioritize regulatory goals, organizational constraints, and complex care provision
resulting in a multilayered, complicated, and unique situation. Findings highlight the need
for creative policy and population health-minded solutions that reflect the practical reality
of providing care in AL/RC settings to promote quality of life for residents.
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Chapter 1. Introduction and Research Aims
Assisted living and residential care (AL/RC) settings serve about 812,000 older
adults with significant care needs in the U.S.1 AL/RC settings provide assistance with
care needs, including activities of daily living (ie, eating, dressing, bathing/showering,
toileting, and mobility), chronic disease management, medications, behavioral
expressions associated with dementia, and cognitive decline. An estimated 42% of
AL/RC residents have dementia, over 70% have cognitive impairment, and more than
75% receive assistance with medication administration.1,2 Most individuals living with
Alzheimer’s disease and related dementias (ADRD) or cognitive impairment experience
behavioral expressions (eg, neuropsychiatric symptoms, behavioral and psychological
disturbances), which have biological, psychological, and environmental underlying
causes and can represent an attempt to communicate unmet needs.3–8
Behavioral expressions in persons living with ADRD are associated with family
and paid caregiver burden and may motivate residential and care transitions.9–12 Though
clinicians, dementia care experts, and researchers recommend nonpharmacologic (ie,
non-medical) interventions to respond to behavioral expressions, individuals’ distress
may persist, which may warrant medical intervention.13–15 Psychotropic medications are
often used to manage behavioral expressions, considered nonstandard, or “off-label”
use.16–18 Antipsychotic medication, specifically in older adults with ADRD, has been
associated with many adverse effects, including increased risk of falls, hospitalizations,
and early mortality.19–23 Coupled with these findings and policy attention in nursing
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homes (NH),24,25 reducing inappropriate antipsychotic medication use (APU) in older
adults has been considered as a quality indicator in AL/RC settings.24,26–28
APU in AL/RC settings is an under-studied and controversial health policy issue.
Clinicians, AL/RC providers, caregivers, pharmacists, and families differ in their beliefs
on the efficacy and risks associated with APU in AL/RC residents, especially those with
dementia.29–32 AL/RC regulations vary by state, so examining an individual state can
provide important policy and practice contexts. It is crucial to investigate why
antipsychotic medications are used and not used in AL/RC populations to understand the
context-dependent administration of these medications beyond NHs.
This dissertation study employs the Institutional Analysis and Development
(IAD) framework to analyze the situation of APU within AL/RC settings, acknowledging
the dynamic and multilevel nature of this issue.33–37 For the research community, this
study uses AL/RC setting-specific data to contextualize decision making and
administration of antipsychotic medications. For policy makers, findings will inform the
Oregon Department of Human Services/Aging and Persons with Disabilities’
(DHS/APD) current and ongoing implementation of an antipsychotic medication quality
metric,38 by providing state-specific evidence and context of antipsychotic medication
use in AL/RC settings. For AL/RC providers and advocacy organizations, this research
will summarize aspects of regulatory noncompliance with psychotropic medications,
describe statewide patterns of APU, and center the perspectives of frontline care staff of
AL/RC residents in Oregon. For clinical practitioners, this research will use the
experiences of AL/RC setting staff and pharmacists to eventually develop a
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considerations fact sheet for the use of antipsychotic medications in their patients. The
long-term objective of this research is to address controversial issues in medication
management in AL/RC populations by developing a context-specific evidence base.
The proposed research is innovative because it embraces the complex, contextual
nature of APU and decision-making in AL/RC settings. Most research on antipsychotic
medication use in long-term care is conducted in NH populations. The American Health
Care Association/National Center for Assisted Living (AHCA/NCAL) currently uses the
quality metric defined by long-stay NH resident data (ie, reducing off-label APU to
15%), which does not address appropriate/inappropriate administration and might not be
relevant to AL/RC settings.26 Due to state variation in AL/RC licensing regulations and
lack of representative longitudinal data, there is little evidence to inform an AL/RCspecific quality indicator for APU. It is crucial to understand APU beyond NH settings to
avoid unintended policy consequences.27,28
The positions and identities I bring to this work inform my framing, analysis, and
conclusions. Though I live with and receive both pharmaceutical and nonpharmaceutical
treatment for mental illness as someone who currently lives independently, managing my
health and social environments, my experience with the research topic at hand is limited
to academic study. I have never worked as a paid caregiver for older persons living with
ADRD, either at home or in a long-term care setting, and I am not an older adult living or
receiving care in an AL/RC setting. Understanding different perspectives regarding APU
in AL/RC settings is a key goal of this study. Building on existing partnerships with local
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and state organizations, I rely on the experience and expertise of external stakeholders to
guide and offer feedback on the implications of this study.
1.1 Specific Aims
Assisted living and residential care (AL/RC) settings serve approximately
812,000 older adults with significant care needs in the U.S. AL/RC settings assist with
managing resident needs such as activities of daily living, chronic disease, health-related
symptoms, medications, and behavioral symptoms associated with dementia.
Approximately 42% of residents have a dementia diagnosis, over 70% have cognitive
impairment, and more than 75% receive assistance with medication administration. Most
older adults with dementia and/or cognitive impairment exhibit behavioral symptoms that
might attempt to communicate unmet needs. More than one-third of AL/RC residents
exhibit such behaviors. These behavioral symptoms are associated with family and paid
caregiver burden and may motivate a transition into or out of long-term residential care.
Psychotropic medications (e.g., atypical antipsychotics, benzodiazepines) are often used
to manage behaviors, which is considered nonstandard use. APU in older adults with
dementia is associated with increased risks of falls, hospitalizations, and early mortality.
Antipsychotic medication administration in AL/RC settings is an under-studied
and controversial health policy issue. Clinicians, AL/RC providers, caregivers,
pharmacists, and families disagree on the efficacy and risks associated with antipsychotic
medications in AL/RC residents, especially those with dementia. AL/RC regulations vary
by state, so examining an individual state can provide important policy and practice
contexts. Oregon currently provides services to an estimated 24,000 AL/RC residents
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across 535 licensed settings, and decreasing APU in this population has been identified as
a public policy priority.38,39 To understand the context-dependent administration of these
medications in settings other than nursing homes, it is crucial to understand why
antipsychotic medications are used and not used in AL/RC populations.
The overall objective of this study is to inform the current debate about
antipsychotic medication policies and practices in Oregon’s AL/RC settings by using
multiple data sources that represent licensing agency, setting, and care provider
perspectives. To acknowledge the dynamic and multilevel nature of this issue, this study
uses the Institutional Analysis and Development (IAD) framework to analyze the
situation of antipsychotic medication administration. Understanding different points of
view regarding antipsychotic medications is a key goal of this study. Thus, a stakeholdergroup will be formed building on existing partnerships with state organizations. I propose
an integrated methods study to examine why antipsychotic medications are administered,
or not, in AL/RC settings to achieve the following aims:
Aim 1: Identify case-profiles of psychotropic medication noncompliance in
Oregon AL/RC settings from 2014-2019. Method. Thematic analysis of public
administrative data of psychotropic medication-related facility citations. I will use
qualitative coding to develop case profiles of organizational noncompliance with state
regulations, and to specifically understand the scope of noncompliance related to
antipsychotic medications.
Aim 2: Examine whether structural characteristics are associated with
prevalence of antipsychotic medication administration among Oregon AL/RC
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settings. Method. Random intercepts regression of four waves of the repeated crosssectional Community-Based Care (CBC) study (2015-2019), adjusting for resident
population characteristics over time.
Aim 3: Describe reasons for antipsychotic medication use and non-use in
Oregon AL/RC settings. Method. I will sample four case communities based on findings
from aims one and two. Within each case community, I will recruit staff to participate in
“think aloud” interviews to respond to a resident behavior scenario or describing an
opportunity for antipsychotic medication administration. Thematic analysis will be used
to qualitatively compare responses from selected communities and staff types.
Impact: Currently, there is insufficient setting-specific evidence to set
appropriate metrics to inform regulations that support the provision of care for AL/RC
residents, especially with dementia. This research will provide multidisciplinary
perspectives on antipsychotic medication use, non-use, and administration decision
making in Oregon AL/RC settings for population-informed and evidence-based state
policy development.
1.2 Dissertating During a Global Pandemic
I proposed the specific aims detailed in section 1.1 at the end of February 2020,
just as worldwide alarms began to sound regarding the novel coronavirus (SARS-COV-2)
pandemic. Nine days after the proposal defense for this dissertation (March 8, 2020),
Oregon Governor Kate Brown issued the first state of emergency due to coronavirus
outbreaks across the state.40 In Oregon, despite accounting for seven percent of total state
cases (total n= 339,556), NH and AL/RC residents comprised nearly half of total state
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deaths (total n=3,959) since the onset of the pandemic.41 The disproportionate impact of
COVID-19 on these settings combined with emergency restrictions and disruption of inperson research activities through the Institutional Review Board inhibited me from
implementing this study as proposed. The original study design relied on in-person,
onsite, long-term data collection in collaboration with approximately four AL/RC
communities in Oregon. Instead, I had to pivot to remote data collection. With guidance
and support from my dissertation committee and external stakeholders, I transitioned the
methods presented in Aim 3 from in-person shadowing of AL/RC staff to remote, semistructured interviews. This change, among other pandemic-associated barriers (eg,
recruitment), significantly impacted my ability to implement this study as truly mixed
methods and a complete situational analysis. I implemented each aim sequentially and
individually, not truly integrating sampling design or analytic approaches. Chapter 2
provides a brief overview of the literature, theoretical, and methodological frameworks
that inform this research study. Chapters 3 through 5 are the empirical articles that align
with the aims proposed in section 1.1. Finally, Chapter 6 weaves together study findings,
reflections, and policy/practice implications of this work. While not fully implemented as
initially proposed, the spirit and intent of this dissertation study remain intact, offering
several considerations for future gerontological researchers, long-term care providers and
clinicians, and state policymakers.
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Chapter 2: Literature Review
The number of older adults (65+ years) in the United States (U.S.) will grow from
49 million to 95 million people by 2060, with the fastest growth among the oldest old (85
years+) category.42 Older age is the most significant risk factor for developing
Alzheimer’s disease and related dementias (ADRD) and the sixth leading cause of death
in the U.S.43,44 By 2050, it is estimated that almost 13 million adults over the age of 65
will be living with Alzheimer’s disease and other related dementias (ADRD).44
Dementia is an overarching term for symptoms that accompany severe neurocognitive
impairment that inhibits a person’s ability to perform everyday activities such as
dressing, bathing, and managing finances, commonly preceded by cognitive
impairment.44,45 The cognitive decline that accompanies progressive symptoms classified
as dementia greatly impacts a person’s ability to live independently; individuals living
with ADRD can experience personality changes, memory loss, behavioral changes, sleep
changes, and ability to perform activities of daily living.5,8,46 In addition to the impacts on
individual health and wellbeing that accompany the development of ADRD, there are
also significant and multilevel psychosocial, financial, service provision, and healthcare
system implications of an aging population with increasing incidence of ADRD.47–49
An estimated 70% of adults who live to the age of 65 will have significant longterm services and supports (LTSS) needs, with approximately one-third using these
services for multiple years.50 Different LTSS options exist along a continuum, ranging
from home health and personal care to skilled nursing facilities.51 This dissertation study
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focuses on one type of LTSS setting: assisted living and residential care (AL/RC), which
is outpacing nursing homes (NH) in terms of availability and utilization.52–54
As the population continues to age, adapting to and caring for the increasing
proportion of those with dementia and cognitive impairment is a community health
imperative. In this chapter, I briefly describe AL/RC as an LTSS option, behavioral
expressions by and management of residents with ADRD in these settings, and the
specific issue of antipsychotic medications as a response to behaviors associated with
dementia. I ground these topics and issues within the Oregon state context.
2.1 Assisted Living as a Long-Term Services and Supports Option
Along the LTSS continuum, AL/RC settings are congregate environments where
administrative, maintenance, and care staff coordinate care and provide services to
residents. AL/RC settings provide housing, social support, medication management, and
some health-related services to older adults and disabilities. Unlike NH, AL/RC settings
are not licensed health facilities and typically rely on paraprofessional, or “unlicensed,”
direct care staff. These settings do not require direct care workers to have healthcertifications such as a certified nursing assistant, licensed professional or vocational
nurse, or medication technician certifications. Individual states regulate assisted living
settings, meaning there are regulatory, operational, and resident population variations.
Settings are meant to have enough staff scheduled to provide care based on the needs of
their resident populations. AL/RC settings are meant to serve individuals who need
assistance with activities of daily living, medication management, household
management, and social support.
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In the U.S., nearly 29,000 licensed AL settings provided care to approximately
812,000 residents.1 Over 40% of these residents have a dementia diagnosis and more than
70% have some level of cognitive impairment.1,2 However, the true prevalence of
cognitive impairment and dementia among older adults are likely higher than reported,
given the under diagnosis of both conditions.46,55,56
2.2 Behavioral Expressions in Older Adults with Dementia or Cognitive Impairment
“Neuropsychiatric symptoms,” “behaviors,” “behavioral expressions,” and
“behavioral and psychological symptoms of dementia” (hereafter, behavioral
expressions) describe the behavioral and affective expressions of both dementia and
cognitive impairment. These include aggression, agitation, anxiety, delusions,
hallucinations, and sleeplessness.5,7,8,57–60 Nearly all older adults with dementia and/or
cognitive impairment experience at least one behavioral expression.4,6,60
Current assessment of behavioral expressions, for clinical or research purposes,
typically capture behavioral events either during or after occurrence and rely on proxy
descriptions of the events.61 Conceptualization and understanding of behavioral
expressions and the antecedents leading to their occurrence influence the response or
treatment. Historically, the geriatric field categorized behavioral expressions as
something purely biological resulting from neurocognitive decline.5 More recently,
clinicians and researchers posit that these behavioral expressions have multiple, diverse
causes, including neurobiological disruptions in the central nervous system, pain, unmet
needs, pre-existing personality/psychiatric conditions, environmental infrastructure, or
over/under stimulation.3–5,62,63 Behavioral expressions can represent an individual’s effort
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to communicate unmet needs such as sensory deprivation, loneliness, physical pain,
activities of daily living, or meaningful activities.3,64,65
It is estimated that more than 34% to 38% of AL/RC residents exhibit behavioral
expressions.2,66 One study found that over 70% of AL/RC residents with a diagnosis of
dementia or cognitive impairment experience behavioral expressions.2 A more recent
investigation discovered that of AL/RC residents who do express behaviors, staff only
documented what caused the behaviors in about one quarter of cases.10 Chronic or severe
behavioral expressions have implications for quality of life, family and caregiver burden,
and care transitions.11,12,67 One study found that behavioral expressions were not
significantly associated with self-assessed quality of life of individuals who experienced
them, but there was a significant association with caregiver assessment of their quality of
life.68 These behaviors are associated with increased family and paid caregiver burden
and may motivate a transition from home to a community-based care setting, or to an
emergency department from long-term care.11,69–71
2.3 Responding to Behavioral Expressions Associated with Dementia or Cognitive
Impairment in Older Adults
There are two overarching approaches to managing behavioral expressions:
nonpharmacologic and pharmaceutical. Nonpharmacologic interventions are behavioral,
psychosocial, or environmental in nature while pharmaceutical interventions are
medications used to treat or manage behavioral expressions. Existing guidelines and
practices encourage psychosocial or environmental interventions as the first line of
treatment in managing behavioral expressions as a person-centered, safe, alternative to
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medication.15,72,73 Nonpharmacologic interventions include sensory, cognitive, and
environmental therapies that can be used to prevent the onset of an individual’s
behavioral expression (eg, aggression, restlessness, wandering) or to mitigate the
behavioral expression.15 These range from care practices to explicit protocols and
therapies. Person-centered care practices such as providing meaningful activities,
incorporating individuals’ preferences, and improving relationships between care
providers and individuals with dementia have been associated with decreased agitation,
depression, and increased quality of life.73–76 Nonpharmacologic therapies to mitigate
behavioral expressions include but are not limited to, aromatherapy, multisensory
therapy, reminiscence therapy, music therapy, validation therapy.4,15
When nonpharmacologic interventions fail or a resident is in considerable
distress, caregivers may try pharmaceutical management of behaviors using psychotropic
medication.77,78 Psychotropic medications interact with the central nervous system and
include the following drug classes: antipsychotics, antidepressants, anxiolytics,
hypnotics, and mood stabilizers.79,80 Clinical guidelines. randomized control trials, and
observational studies suggest the use psychotropic medications in older adults,
particularly antipsychotic medications in those with dementia or cognitive impairment,
are associated with greater risks than benefits.20,81–85 Specifically, antipsychotic
medication use in older adults with dementia has been associated with an increased risk
of potential medication-related side effects,86 falls,87 hospitalizations,23,88 and early
mortality.19,21,22,89–91 Understanding why antipsychotic medications are used among older
adults with dementia is a safety, quality of life, and public health issue.92
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2.4 Antipsychotic Medications Use Disparity in Older Adults with Dementia
Antipsychotic medication use (APU; prescription and administration) in AL/RC
settings is an under-studied and controversial health policy issue. In response to findings
regarding the risks associated with APU in older adults with dementia, the U.S. Food and
Drug Administration first issued a boxed (“black box”) warning for APU in older adults
in 2005, which has been associated with lower antipsychotic use among older adults with
dementia.93–95 The Alzheimer’s Association best practices for dementia care recommends
the use of antipsychotic medications in individuals with dementia only after attempting a
nonpharmacologic approach and under the following conditions: 1) behavioral symptoms
due to psychosis, 2) symptoms put an individual or others in danger, or 3) experiences of
inconsolable, persistent distress or substantial difficulty receiving needed care.13,15,96
However, antipsychotic medications are prescribed for conditions outside of approved
indications, or “off-label,” to manage behavioral expressions.17,18,97,98 Overall, AL/RC
administrators, direct care and nursing staff, and families of AL/RC residents reportedly
view the use of these medications positively and effectively.29–31,99–101 Despite current
initiatives that focus on reducing antipsychotic use in the NH population,25,102–104 there is
still lack of AL/RC-specific evidence regarding how APU, staff training and
implementation of nonpharmacologic interventions, uptake of other psychotropic
medications beyond antipsychotics, or potential discrimination against older adults whose
behaviors are deemed “challenging.”12,63,105–109 The current debate regarding when or if to
use antipsychotic medications to respond to behavioral expressions creates a complex
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situation with multidisciplinary actors that is difficult to solve with “one-size fits all”
policies.27,110
2.5 Assisted Living/Residential Care Context in Oregon
AL/RC settings are licensed and regulated by individual states; examining a
single state can provide important policy and practice contexts.111–114 Oregon is
considered a regulatory and care provision pioneer of modern day AL/RC in the
U.S.115,116 In Oregon, an estimated 18.2% of the population (767,628 people) are 65 years
or older.117 Oregon’s older adult population is anticipated to reach more than 20% by
2030.118 A recent study estimated that 70% of adults who age into older adulthood (65
years or older) will develop significant LTSS needs and nearly half will receive some
form of paid care over the course of their older adult years.50 In the last decade, the
number of AL/RC settings has increased while the number of NH settings has
decreased.53,54,119 AL/RC settings in Oregon have increased by 9.4% overall (489 in 2014
to 535 in 2019), with a 30% increase in settings endorsed to provide memory care (148 in
2014 to 193 in 2019).120,121
AL/RC setting types in Oregon include assisted living (AL), residential care (RC),
and memory care (MC) communities. RC settings have different physical environments
from AL but operate under the same regulations.122 MC communities can either be standalone buildings, or units within AL/RC endorsed to provide ADRD-specific care.123
Oregon collects longitudinal data on the AL/RC population including setting-level
prevalence of APU. Over 24,000 Oregon residents currently receive supportive health
and housing services within AL/RC settings in Oregon.121 This state study shows that
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47% of current residents have a dementia diagnosis, and 27% took an antipsychotic
medication in the prior 30 days. However, these rates differ by setting type: 17% of AL,
30% of RC, and 44% of MC residents reportedly received an antipsychotic medication in
the prior 30 days.121 These estimates are higher than APU rates reported by NH in
Oregon (15%)124 and nationally (14%).104
In observational studies of NH, both resident (eg, gender, age, behavioral
expressions, dementia diagnosis, Medicaid coverage) and setting (eg, profit status,
geography, occupancy rate, staff mix) characteristics have been correlated with higher
APU rates.125–128 Studies suggest pain and behavioral expressions of long-term care
residents with ADRD remain underrecognized and undertreated.129–131 Few studies that
have examined AL/RC setting and resident characteristics associated with antipsychotic
use found mixed evidence that setting size, geography, resident age, gender, ADRD
and/or psychiatric diagnosis, and expression of behavioral symptoms were associated
with APU.23,132,133 A cross-sectional study of Oregon AL/RC residents found that
residents living in MC settings, expressed more behaviors, and had a diagnosis of ADRD
were more likely to receive an antipsychotic medication in the last week compared to
their counterparts, and residents living in nonprofit settings were less likely to receive an
antipsychotic medication.134 However, associations among organizational and resident
characteristics and rates of APU have not yet been explored at the population-level (ie,
state). AL/RC settings need guidelines that respond to the context of the organizational
environment and changes in the resident population that are not copied from NH research
and policies.
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APU in AL/RC settings is a public policy priority in Oregon from a safety,
oversight, and quality perspective and involving multidisciplinary actors evidenced by
updates to licensing regulations and recent legislation focused on this topic. Oregon
Administrative Rules Chapter 411 Division 54 (OAR 411-054-0000) govern licensing,
quality, and oversight of AL/RC settings.122 OAR 411-054-0055-6 addresses the use of
psychotropic medications, including antipsychotics, in AL/RC residents. Specifically,
AL/RC settings may only use these medications to treat a resident’s medical symptoms or
maximize functioning; cannot request psychoactive medications to treat behavioral
symptoms without clinical consultation; and must document initial non-pharmacologic
interventions before administering psychotropic medications on an as-needed basis.
State surveyors conduct inspections, interview staff and residents, and review
resident records to assess regulatory compliance at least once every 24 months for
AL/RC settings. AL/RC settings may be cited for regulatory noncompliance, determined
based on the severity and scope of the violation. Medication treatment orders (C303),
medication administration (C310), and psychotropic medications (C330) are consistently
ranked in the top fifteen most frequent citations for noncompliance among Oregon
AL/RC settings.135
In the 2017 legislative session, Oregon passed two bills regarding quality of care
in AL/RC settings. House Bill 3359 introduces additional quality oversight, such as
developing the Quality Metrics Council (QMC) comprising state policy makers, AL/RC
representatives, clinicians, and academic experts, and requiring AL/RC settings to have
policies and procedures in place to reduce medication errors.136 House Bill 3262
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introduces additional oversight intended to reduce adverse side effects and nonstandard
long-term APU in older adults and persons with disabilities in long-term care.39 However,
some QMC members have raised concerns that the goal of reducing APU will result in
unintended consequences that may harm individuals with serious mental illness, or result
in residents with behavioral expressions being transferred out of AL/RC settings.137,138

Table 1. Dissertation stakeholder advisory committee
Name

Organization

Position

Lynette Alvarado

Concepts in Community
Living

Regional Director of
Operations

Linda Bifano, DNP, RN,
MPA

Bifano Consulting, LLC

Community-Based Care
Services Consultant

Lindsey Bretzman

Mary’s Woods

Dementia Life Enrichment
Specialist

Nirmala Dhar, LCSW

Oregon Health Authority

Statewide Older Adult
Behavioral Health
Director

Mauro Hernandez, PhD

ita Partners

Principal

Linda Kirschbaum

Oregon Health Care
Association

Senior Vice President of
Quality Services

Nancy Koerner, RN

Mary’s Woods Retirement

Vice President of Health
Services

Maureen Nash, MD, MS,
FAPA

Providence Elderplace

Geriatrician Psychiatrist,
Medical Director

Stakeholder engagement and collaboration is critical to achieve the long-term
objective of this research due to their contributions to the development of and familiarity
with Oregon’s sociohistorical AL/RC policy and practice context. Representatives from
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key organizations including the Oregon Department of Human Services/Aging and
Persons with Disabilities (DHS/APD), Oregon Health Care Association (OHCA), Quality
Metrics Council (QMC), LeadingAge Oregon, Oregon Partnership for Quality Dementia
Care, and AL/RC providers will be asked to review and comment on data collection
tools, to provide their organization's policies regarding APU, and respond to draft
findings. I have recruited representatives of these organizations to form a stakeholder
advisory committee (see Table 1). This committee will serve in part to establish research
priorities, dissemination, and future directions for this work.
2.6 Medication Management in AL/RC Settings
Medication management in AL/RC settings is a complex process involving
residents, direct care staff, nurses, prescribers, pharmacists, and administrators.139–144 As
with all other operations in AL/RC settings, administrators are responsible for “ensuring
adequate professional oversight of the medication treatment administration system”
(OAR 411-054-0055-1a).122 Medication administration in Oregon AL/RC settings must
also be reviewed quarterly by registered nurses or pharmacists (OAR 411-054-0055-1i).
Direct care staff (eg, caregivers, certified nursing assistants, and medication aides) build
and maintain relationships with their residents, learning from and basing their care
decisions on residents’ cognitive, physical, and emotional cues on a daily basis.141,145,146
In Oregon, direct care staff can assist with medication administration if supervised by a
nurse.140,147 For those staff that assist medications administered “as-needed,” knowing
individual residents’ behaviors and nuances is critical to decision making around
administration.141 Direct care staff may view behavioral and psychological expressions of
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dementia negatively,12 and have several strategies to address these behaviors, such
redirection, isolation, seeking other coworkers’ assistance, or communication with
external care providers.148 However, little is known about direct care staff and nurse’s
decision making and task-related responses to these behaviors. Few studies have
examined how and why antipsychotic medications are used in AL/RC settings by
incorporating multidisciplinary perspectives and data sources.
2.7 Institutional Analysis and Development (IAD) Framework
Institutions describe situations of human actions structured through rules, norms,
and shared strategies.33,149 This “grammar of institutions”149 is the foundation of the
Institutional Analysis and Development (IAD) framework, which identifies the key
variables and components, including environmental and community characteristics and
rules or norms, which contribute to an “action situation.”35,36,150,151 An action situation
consists of actors that occupy certain positions and perform actions relative to other
actors involved (Figure 1).36,151 These positions and actions are also influenced by
external variables, including available information, actors’ level of control within the
situation, and costs and benefits associated with actions taken, resulting in various
interactions and outcomes.36,37
AL/RC settings are organizational contexts where residents, their families, direct
care staff, administrators, clinicians, regulatory entities and other nonhuman elements
(eg, service plans, resident records, treatment orders) interact through social and care
relationships (Figure 1).152–154 At each contextual level shown in Figure 1 are different
sets of actors, choices, positions, available information and influence, thus constituting
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different levels of analysis: the action situation (operational), authoritative decision
making (collective choice), and the mechanisms by which collective choice is enacted
(constitutional).35–37,150

Figure 1. Multilevel nature of assisted living/residential care (AL/RC) settings.

As conceptualized through the IAD framework, I position the AL/RC setting of
care as an “institution” that frames the action situation of APU. Figure 2 maps the study
elements of this dissertation onto an adaptation of Ostrom’s conceptual model of the IAD
framework.36
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Figure 2. Adapting the Institutional Analysis and Development framework to
antipsychotic medication use in assisted living/residential care settings.

Note. Adapted from E. Ostrom. Background on the institutional analysis and development framework.
Policy Stud. 2011;39(1):10.

The IAD framework highlights the multilevel and contextual nature of the overall
dissertation study and assists with identifying “the elements and general relationships
among these elements to consider for institutional analysis and organize diagnostic and
prescriptive inquiry.”151 In this study, I am interested in analyzing APU within AL/RC
settings as an action situation. Actors involved include residents, direct care staff,
medication aides, administrators, clinical providers, therapists, pharmacists, prescribers,
state surveyors, and state policymakers. To understand the how and why behind APU in
AL/RC settings, I use this framework to identify the other elements of this action
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situation: types of information, level of control, costs/benefit in decision making,
positionality, and interactions among human, organizational, and material actors.
The IAD framework was formulated and adapted to study policy processes and
socioecological systems, primarily used at the intersections of policy, governance,
economy, and ecology, where external variables that influences an action situation (ie,
biophysical conditions and community characteristics) have largely been conceptualized
as elements of political or ecological environments.155–157 I have adapted the biophysical
conditions described in the original framework to focus on material and structural
conditions of AL/RC settings, such as geographical designation (ie, urban and rural),
setting size, and license type (ie, AL/RC or MC endorsement). Additionally, community
characteristics in the original framework describe the social and cultural context where an
action situation takes place.37 I operationalize community characteristics with measures
that describe the resident population within any one AL/RC setting (eg, proportion of
residents with ADRD, proportion of residents with behavioral expressions). These
measures only partly frame the situation of APU but provide context of the resident
population within settings. Finally, the rules and norms that structure an action situation
include the rules and regulatory parameters outlined through state licensure and staff
training requirements.
These external variables influence what occurs within an action situation,
resulting in outcomes. For this study primary outcomes of interest include the rate of
APU in Oregon AL/RC residents and decision points regarding whether to administer
antipsychotic medications. Interactions among the actors involved in the situation also
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play a role in determining the actions that take place and affects outcomes. Evaluative
criteria are used by actors within the situation and/or observers of the situation, such as a
doctoral student researcher, to identify areas of improvement and mechanisms that work
well.36,37
2.8 Situational Analysis: Examining Social Worlds
In section 1.1, I briefly describe the research methods associated with each of the
three proposed aims of this dissertation study. In Chapters 3-5, I detail the specifics of the
methods conducted to achieve these study aims. This section defines and describe the
overarching philosophy and research methodology guiding the entire dissertation study:
pragmatism and situational analysis. Briefly, pragmatism is a philosophy of meaning
making that frames my approach to forming and pursuing the answer to the research
question: How and why are antipsychotic medications used in AL/RC settings?
Pragmatism emphasizes the pursuit of actionable knowledge (eg, applied knowledge),
recognizing that knowledge is situated in prior experience and beliefs that inform action,
and that multiple realities or truths exist based on this situated knowledge.158–162 A
foundational element to this dissertation study is understanding how beliefs, actions, and
situated knowledge inform APU in AL/RC residents by critically evaluating multiple data
sources, perspectives of different actors, and considering the multilevel contexts of
AL/RC settings.159
Pragmatism guides my approach to situational analysis, which I use to weave
together findings across the three proposed research aims to understand APU in AL/RC
settings in Oregon. Clarke developed situational analysis as an extension of grounded
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theory methodology.163 Grounded theory processes comprise integrated, iterative
qualitative data collection and analysis, extensive reflexivity through analytic memos,
and categorization of concepts to generate theory derived from —grounded— within the
data.160,164–166 Grounded theory methods generally involve processes of coding, memoing,
and theorizing over the course of data collection, where the researcher contemplates and
interprets the patterns, topics, and concepts arising within the data.160,166
Situational analysis builds on the Straussian conceptualization of social worlds
and negotiations.163,167–170 Strauss theorizes social worlds as universes of response,
organization, and communication that can exist at any scale and subsist of limitless
different subworlds, or segments.167,170 Building on prior work of Carder, the social world
under investigation in this dissertation is the AL/RC setting.171,172 The segment, or
situation, of interest is APU, which consists of human (eg, staff, residents, prescribers)
and nonhuman (eg, antipsychotic medication, training, medication records) actors that
interact together to negotiate social processes around medication administration.172
Situational analysis extends grounded theory by providing a method to identify,
conceptualize, analyze, and visualize the situations which construct the processes that
occur within a social world.163,166,173–177
As described in section 2.7, APU within AL/RC settings is the action situation of
interest for this study, therefore, the unit of analysis. In addition to coding procedures and
identifying elements within data, situational analysis consists of various data mapping:
situational maps, social worlds maps, relational maps, and positional maps.173,174,176
Situational maps identify all the of the relevant elements of the action situation: human,
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nonhuman, ideological, discursive, symbolic, cultural, historical, temporal, etc.163,173,175 I
provide two examples of situational maps, one in Chapter 5 pertaining to my third
research aim and in Chapter 6 attempting to comprehensively describe APU in AL/RC
across the entire dissertation study. One can use social worlds maps to draw out the actors
(human and nonhuman) pertinent to a situation of interest and where they orient to the
situation of interest to provide an understanding of the overarching discourses,
negotiations, and interactions that take place.163,175 For example, AL/RC residents and
care staff may operate within the arena of an AL/RC setting. Similarly, pharmacists,
clinicians, and prescribers primarily perform within the context of the healthcare system
(ie, clinics, offices). Finally, state legislators operate in the realm of regulations and
policy construction. Relational maps attempt to make connections among the relevant
elements identified in a situational map and positional maps plot the major positions
identified regarding the situation of interest.
While the IAD framework acknowledges the dynamic nature of processes at a
given contextual level through the feedback loop from outcomes to both external
characteristics and the action situation (Figure 2), the action situation itself is linear (eg,
actors → positions → information → decision → outcome). By utilizing the components
of an action situation identified by the IAD framework and previous research on
antipsychotic medication administration in this setting, an informed grounded theory
approach will guide my descriptions and composition of the action situation.
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Figure 3. Institutional analysis and development framework operationalized through
situational analysis.

Situational analysis provides an approach to operationalize the IAD framework in
the context of this study (Figure 3). Both Ostrom’s framework and Clarke’s
methodological application work with the concept of an action situation, embracing
complexity and context to explain and situate various phenomena. The research question
and action situation influence the type of mapping used. In addition to the methods used
to achieve the aims proposed in Chapter 1, I use situational analysis to draw conclusions
across the overall dissertation study.
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Chapter 3: Paperwork, Paradox, and Pro Re Nata: Psychotropic Medication Deficiencies
in Assisted Living/Residential Care
3.1 Abstract
Background: A significant proportion of assisted living/residential care (AL/RC)
residents live with Alzheimer’s disease or related dementias (ADRD) or cognitive
impairment, conditions associated with behavioral expressions that may or may not be
treated with psychotropic medications. Individual state approaches to AL/RC licensing
and oversight in the United States result in different practice standards and requirements,
including psychotropic medication use.
Methods: We use applied thematic analysis to examine the scope of 170 psychotropic
medication deficiency citations issued in Oregon AL/RC settings from 2015-2019.
Results: We found most deficiency citations were issued for documentation errors
regarding nonpharmacologic approaches and residents’ behavioral expressions. Other
themes include direct care workers’ role paradox, lack of clinical consultation before
requesting psychotropic medication order changes, and organization-level correction to
prevent future deficiencies.
Discussion and Implications: Policymakers might consider how regulations
unintentionally incentivize task-oriented versus person-centered care practices and
incorporate AL/RC provider experience during policy development.
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3.2 Introduction
In the United States, approximately 29,000 assisted living/residential care
(hereafter ‘AL/RC’) settings provide a community-based long-term care option to over
800,000 residents.1 A significant share of AL/RC residents have an Alzheimer’s disease
or related dementia (ADRD) diagnosis (42%), and an estimated 26% to 90% have
cognitive impairment.1,2 Psychotropic medication used to manage behaviors associated
with ADRD in long-term care including AL/RC residents,103,133,178 presents a significant
health policy concern because of their associations with adverse events and implications
for care provision.25,110
Psychotropic medications—antipsychotic, antianxiety, antidepressant, sedatives,
and hypnotics—are commonly used to respond to behavioral expressions in people living
with ADRD.16,18,78 If nonpharmacologic (eg, psychosocial) interventions do not alleviate
an individual’s distress, medication may be used.77,96,179,180 The appropriateness
of psychotropic medications to manage behavioral expressions associated with ADRD
and cognitive impairment has received national and international attention.178,181–183
3.2.1 Psychotropic Medication Deficiency Citations: What Can We Learn?
In skilled nursing facilities, national regulatory standards and resident-level data
collection have led to the development of national quality metrics (eg, Nursing Home
Compare); the pursuit of quality can theoretically lead to better care processes and
outcomes.184,185 When defining “quality,” long-term care settings include deficiency
citations, or measures of organizational noncompliance with regulations.186–188
Deficiencies have been associated with quality of the physical environment, staff
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turnover, resident safety, and resident-centered care.189–191 Compared to other types of
medication-related citations, the prevalence of psychotropic deficiencies is low and
mainly consists of documentation errors.192,193. Less is known about associations of
AL/RC deficiency citations with resident outcomes, though existing research suggests
most deficiencies do not pose severe risk to residents’ health and safety, and that most
medication errors are related to documentation.188,194–196
Individual states oversee AL/RC regulations resulting in wide within and between
state variations of licensing standards, staff training requirements, and
admission/discharge criteria, limiting the utility of measuring and comparing quality of
facilities across states.111,114,140,197 States, including Oregon, conduct periodic surveys of
settings to evaluate regulatory compliance, issuing surveys when deficiencies are
observed with licensing standards.114 Depending on a violation’s pattern and severity,
Oregon’s AL/RC settings may have to pay a financial penalty, ranging from less than
$1,000 to over $5,000.198
In Oregon, state licensing agents conduct inspections at least once every 24
months in AL/RC and memory care-endorsed (MC) settings.122,123 Surveyors inspect
facility records, including each resident’s medication administration record (MAR),
which documents the orders (e.g., dose, route, timing), whether the medication is
scheduled or pro re nata (PRN; as needed), and any pertinent side effects or interactions.
Staff may administer medications, including psychotropic classes, on a PRN basis to treat
acute symptoms or supplement scheduled medications.122 AL/RC staff must describe the
parameters for PRN use, individualized to residents. For example, the MAR for a resident
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with a PRN psychotropic medication order for “anxiety” or “aggression” must include a
specific description of how that resident exhibits both “anxiety” and “aggression” and
non-pharmacologic efforts that staff should attempt before administering
medication.78,141,199
Little is known about regulatory deficiencies in AL/RC settings, and even less
about medication-related deficiencies. Within the AL/RC context, direct care staff roles
present an additional layer of complexity to understanding organizational compliance
with medication administration regulations.200–202 These staff are first line responders to
residents’ behavioral expressions but cannot formally assess or evaluate.12,141,142,203 This
study employs applied thematic analysis to examine patterns of organizational
noncompliance with psychotropic medication AL/RC rules in Oregon.
3.3 Methods
3.3.1 Data Sources
This study uses publicly available administrative documents from Oregon’s LongTerm Care Licensing website.204 This website hosts the last five years of routine
inspection and complaint investigation reports, which contain deficiency citations. We
downloaded psychotropic medication deficiency citations (C330 tags) issued from 20152019 into Microsoft Excel (n=170) and then imported into ATLAS.ti, a qualitative
analysis software.205 Deficiency citations include three types of violations: abuse,
licensing, and failure to self-report. Licensing violations represent “failures to
substantially comply with licensing rules” as determined by the survey team and include
narratives that describe the nature of the violation.198 Along with the deficiency citation,
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surveyors and AL/RC staff co-develop “plans of correction” describing the actions staff
and management plan to take to both reconcile the deficiencies and prevent them from
reoccurring. Plans of correction address the following questions: “what action will be
taken to correct the rule violation?”, “how will the system be corrected so this violation
will not happen?”, “how often will the area needing correction be evaluated? and “who
will be responsible to see that the correction area is completed/monitored?”
Setting characteristics include licensed capacity (number of beds), license type
(AL/RC and MC), whether the setting accepts Medicaid clients, geographic designations
(urban/rural), and ownership status (profit/nonprofit). Other sources for setting
characteristics include publicly available rosters of the currently licensed AL/RC/MC
settings in Oregon (DHS Rosters), the Oregon Office of Rural Health geographic
designations by zip code,206 and Oregon Secretary of State’s Business Registry.207
3.3.2 Applied Thematic Analysis
Applied thematic analysis results in identification and description of implicit and
explicit ideas within a textual data set.208,209 We aim to identify descriptive and latent
themes associated with AL/RC settings’ organizational noncompliance with psychotropic
medication regulatory requirements. In this study, we used both deductive and inductive
coding approaches, reflective memos to describe emergent themes, and discussion among
authors to determine interrater reliability. Thematic analysis lends itself to both deductive
and inductive coding procedures to further contextualize and reflexively identify
overarching patterns.210,211 Oregon Administrative Rules found in Chapter 411 Division
54 Section 55-6 were used to deductively define the initial set of codes.122 These codes
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parallel the reasons a setting could be cited for noncompliance: “lacking documentation
of attempted Nonpharmacological interventions,” “lacking evaluation and service
planning for Nonpharmacological interventions prior to requesting psychotropic
medications,” “lacking documentation of resident-specific parameters for use of
psychotropic medication,” and “not consulting a health professional prior to requesting
psychotropic medication.” Reading through the deficiency citations revealed patterns
related to the deficiencies beyond explicit regulatory noncompliance, leading to the
formation of additional codes: the types of psychotropic medications used, whether
multiple psychotropic medications were ordered for the same resident, the reasons
medications were prescribed, staff roles implicated, and immediate and long-term
strategies to reconcile the deficiency and prevent it from happening in the future (e.g.,
updating resident-specific parameters and nonpharmacologic interventions,
comprehensive administration record audits, in-service training for care staff and
management).
The entire citation was considered the unit of analysis, however the authors noted
when multiple residents were discussed within the citation. For example, a citation could
only reflect deficiencies found within one resident’s medication records, among multiple
residents’ records, or general staff practices (not specific to any resident). If a surveyor
indicated they reviewed three residents’ records and found that two of those records
lacked documentation of nonpharmacologic practices, those deficiencies would be coded
separately for each resident. The authors individually coded the same ten deficiency
citations and discussed coding decisions and additional considerations for interpreting
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surveyor comments. The first author maintained analytic memos to describe emergent
themes while coding and discussed findings with the second author during biweekly
meetings over a four-month period.
3.4 Findings
3.4.1 Setting Characteristics
Between 2015-2019 state surveyors issued 170 psychotropic-medication (C330)
citations to 152 AL/RC settings (~30% of all settings). Most settings that received C330
citations had an MC endorsement (54%), followed by 29% AL only, and 17% RC only.
Nearly all cited settings operated as for profit (96%), and over half were in urban counties
(55%), compared to 38% in rural counties and 5% in frontier counties. Eighty percent of
the cited settings accepted Medicaid payment. Capacity ranged from seven beds to 153
beds, and two-thirds of settings had a capacity of 54 beds or less.
Among AL/RC settings who received a C330 deficiency citation between 20152019, surveyors examined at least 292 residents’ records with PRN psychotropic
medications. Surveyors found deficiencies in 251 (86%) of these records. The primary
reasons for deficiency citations included lack of documentation of attempted
nonpharmacological interventions and resident-specific parameters indicating use of PRN
psychotropic medications, and lack of consultation with healthcare providers prior to
requesting PRN psychotropic medications. Emergent themes and related subthemes are
detailed below.
3.4.2 Theme 1: Resident records lacked detailed documentation of administration
instructions and attempted nonpharmacologic interventions
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Documentation errors comprised the vast majority of psychotropic medication
deficiencies. Across the 170 citations, lacking documentation of attempted
nonpharmacological interventions and resident-specific parameters were coded 188 and
130 times, respectively. Residents’ medication administration records cited for lacking
documentation of nonpharmacological interventions encompassed several scenarios. The
most frequently recorded scenario was that residents’ records lacked evidence that
nonpharmacologic interventions were developed or attempted and failed to specify
behavioral descriptions indicating the need for a PRN psychotropic medication. For
example,
“There was no documentation non-drug interventions had been attempted
with ineffective results prior to administering the PRN psychotropic
medication. Progress notes for the dates given showed inconsistent
references to failed interventions, and no description of the behavior that
required the medication.”
Sometimes nonpharmacologic interventions had been developed for staff to attempt, but
not documented on the administration record:
“Staff were to try at least three non-drug interventions prior to giving
Ativan, which were listed beneath the Ativan order. During 2/2015,
Resident 6 was given PRN Ativan on 18 occasions for "yelling" or
"yelling and agitation." On 15 occasions, there were no documented nondrug interventions attempted prior to giving the Ativan. Results were not
documented on most of the occasions. During 3/2015, Resident 6 was
given PRN Ativan on 20 occasions for "yelling" or "yelling & agitation."
No non-drug interventions were indicated on any of the occasions and
results were not indicated on most of the occasions.”
Subtheme 1a. Response to residents’ behavioral expressions are not customized
to the individual. Settings that documented available nonpharmacologic interventions for
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staff to attempt did not ensure these interventions were individualized to any particular
resident:
“There was no documented evidence the facility had written resident
specific non-pharmacological interventions to be tried prior to
administration. In an interview, 3/27/18 at 12:43 pm, Staff 7
[caregiver/medication aide] confirmed the facility used the form,
"Behavior Interventions Before Using", for all residents who were
prescribed PRN behavior medications. The form had a list of eight nondrug interventions to try prior to administration, however was not resident
specific.”
Often PRN psychotropic medication parameters included a one-word rationale (eg,
anxiety or agitation). Surveyors noted that residents’ records were lacking descriptions of
how residents expressed clinical indications such as “anxiety,” agitation,” “restlessness,”
or “paranoia.” For example, one citation described a resident’s PRN psychotropic
medication orders:
“Resident had signed physician orders for the following PRN psychotropic
medications to treat behaviors: Haloperidol 0.5 ml every 4 hours as needed
for agitation or nausea. Lorazepam 0.5 mg tablet every 4 hours as needed
for anxiety or breathing problems associated with anxiety. Resident 1's
MARs, reviewed between 4/1/18 and 6/10/18, revealed the following
deficiencies: The MARs failed to include resident-specific parameters
which described how Resident 1 exhibited "agitation" and "anxiety." As a
result, staff were unclear as to when to administer each medication.”
3.4.3 Theme 2: Unclear parameters place direct care workers in a role paradox.
In some circumstances, the prescriber’s instructions for medication administration
left room for interpretation, placing unlicensed direct care staff in a position to overstep
their defined roles. Staff who administer PRN medications were left to decide how to do
so if MARs did not describe residents’ behaviors or medication indications. For example,
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one resident had a medication order for a PRN antipsychotic medication with multiple
dosages,
“The current MAR indicated PRN Haloperidol Lactate Concentrate 2
mg/ml for delirium or nausea - give 0.25 every 4 hours, or give .5 every 4
hours. Non-licensed staff were left to decide which dose of Haloperidol to
administer and what behavioral symptoms the resident might exhibit
indicating a need for the medication.”
Another resident had multiple PRN orders for psychotropic medications for “anxiety,”
“sleep,” and “agitation.” However, the lack of specific parameters left room for
unlicensed care staff to interpret when to give which medication,
“The current MAR included lorazepam (anti-anxiety), one to two tablets
every four hours as needed for "anxiety or sleep" and haloperidol
(antipsychotic) 2 mg/ml concentrate 0.5 ml by mouth or under tongue
every 6 hours as needed for "agitation." Non-licensed staff were left to
decide how many tablets of lorazepam to administer and what behavioral
symptoms the resident might exhibit indicating a need for the medication.
Staff were also left to decide how Resident 3 might exhibit agitation,
indicating a need for PRN haloperidol.”
Sometimes residents receive PRN psychotropic medications for reasons not
prescribed or indicated as a parameter. For example, one resident had a PRN
benzodiazepine order for “anxiety or shortness of breath.” The surveyor noted the
following deficiency,
“Resident was administered Lorazepam for "agitation and aggression".
There was no documented evidence that Resident 1 was displaying anxiety
or shortness of breath when the medication was administered. On
11/18/18, she was administered Lorazepam for "agitation and
inappropriate behaviors" and there was no documentation that nonpharmacological interventions were tried and ineffective before the
medication was given.”
3.4.4 Theme 3: Disconnect regarding when to seek qualified expertise prior to requesting
psychotropic medication from residents’ primary care providers
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AL/RC operators and staff must consult with a licensed healthcare professional
prior to requesting psychotropic medications to determine appropriateness and rule out
other potential causes of concern. Surveyors issued deficiency citations when unlicensed
AL/RC staff requested psychotropic medications without first consulting with the facility
RN. For example,
“Resident’s progress notes and interviews with staff revealed unlicensed
staff contacted the physician on multiple occasions to request routine and
PRN psychotropic medications to treat behavioral symptoms. There was
no documented evidence Staff 3 (RN Consultant) was consulted or
directed staff to contact the physician.”
These citations included evidence of direct care staff or administrators contacting
physicians’ offices directly through fax and requesting medications by name or asking for
medications to treat specific behaviors:
“A fax was sent to the resident's physician from caregiving staff. The fax
indicated ‘Can we have an order for Lorazepam PRN for [resident name].
[They have] an order for Lorazepam 0.5 mg- 1/2 tab before showers. Res
seems very anxious, aggitated [sic]. Screaming and yelling. Thank you.’
The physician responded with the order as requested. There was no
documented RN assessment of the need for an increase in the resident's
Lorazepam order.”
Subtheme 2a. Working with third party hospice services and staff introduces
complexity and confusion about responsibility. Oregon rules require clinical
consultation prior to requesting psychotropic medications except for hospice recipients,
though other PRN psychotropic requirements remain. For example, one setting received a
citation for lacking resident-specific parameters and evidence of nonpharmacologic
interventions for a resident receiving hospice services,
“Resident 2 had orders for Lorazepam PRN for anxiety or insomnia and
Haldol PRN for agitation and/or hallucinations. A description of the
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behaviors that warranted the medications was lacking and there was no
documented evidence other factors had been ruled out for the resident's
behaviors including pain, and lack of bowel management. Non-medication
approaches to attempt were not identified and per the 3/1-3/31 and 4/14/30/19 MAR noted "not applicable-Hospice." There was no order from
Hospice to not attempt non-medication approaches.”
Subtheme 2b. Interdisciplinary collaboration can mitigate role confusion. Often
registered nurses oversee medication management. Some organizations may contract with
a consultant pharmacist to assist with medication review and recommendations. One
setting described collaborating with their institutional pharmacy to ensure clarity and
presence of appropriate clinical indications and PRN psychotropic medication orders,
“The Executive Director and RN will meet with the institutional pharmacy
to ensure that the prn parameters created by the nurse will be carried over
onto the electronic medication administration records when the pharmacy
sends out refill cards. There are times that those parameters are not carried
over when the pharmacy updates the medical records to match the new
barcode on a bubble pack card within the electronic system. The RN will
inservice [sic] medication aids to ensure they understand the importance of
documenting their attempts at non-pharmacological interventions prior to
administration of PRN psychotropics.”
3.4.5 Theme 4: Going through the motions or driving change: Who are plans of
correction for?
To prevent future deficiencies, setting staff must propose a system change.
For example, some settings provide care staff with a visual cue in the form of an
order note, “All residents with orders for PRN psychotropic medications will have
non-pharmacological interventions added to their MARS as an ‘attempt first
order’” or require action within the electronic administration record, “Intervention
check boxes will be added to the MAR and interventions must be entered before
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staff can document medication administration.” Plans of correction varied in level
of detail and specificity across settings.
Another common proposed plan of correction includes conducting in-service
training on medication management, administration, documentation, and regulations for
care staff, medication technicians, and management staff (e.g., executive director,
administrator, registered nurses). Surveyors described training as both in house
(conducted by the affiliated registered nurse) or external educators (e.g., consultant
pharmacist). Plans of correction did not detail the content or frequency of these training
sessions. Some settings described interdisciplinary plans of correction that included
multiple types of staff within the setting, residents’ families, pharmacists, and physicians.
One setting planned to implement daily PRN medication order checks, tracking of PRN
administrations, and updating training for new hires:
“Resident Coordinators will check daily through all given PRN
medications and check documentation of their staff to ensure all prior nonpharmacological interventions had been attempted and documented before
administering the medication. Resident Coordinators will report monthly,
to nursing, if any PRN medications are being used 3 or more times in a
month. This will ensure accurate tracking by the nurses or nurse
practitioners of the frequency of PRN's given. During the end of the month
medication cycle fill, the Resident Coordinators will double check each
medication order to ensure that reasons for use are added and
parameters/steps are clear. While training new staff all supervisors will
teach required residential care rules around using PRN psychotropic
medications and proper non-pharmacological interventions and
documentation for each resident in their home.”
3.5 Discussion
Although psychotropic medication administration rates have been examined, to
our knowledge, this is the first qualitative analysis investigating the scope of
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psychotropic medication deficiency citations in AL/RC settings. This study provides
important context for understanding state oversight and enforcement of this important
quality of care topic. Over half of settings that received a psychotropic medication
citation had an MC-endorsement. This is expected given higher use of psychotropic
medications among individuals with an ADRD diagnosis.17,32,108,212 In Oregon, an
estimated 44% of MC residents received an antipsychotic medication in the prior 90-day
period, compared to 17% in AL and 21% in RC settings.121
Most citations addressed a lack of documentation of attempted nonpharmacologic
practices or resident-specific descriptions of behaviors that warrant administration of a
PRN psychotropic medication. This echoes findings of other studies suggesting the
majority of deficiency citations issued in long-term care settings do not present imminent
danger to residents.24,188,189,191,192 Lack of documentation might not mean that staff did
not attempt a nonpharmacologic intervention prior to administering a PRN psychotropic
medication. However, AL/RC operators’ documented reasons for attempted
nonpharmacologic interventions provides one level of evidence to state surveyors that
required practices actually occurred. Documentation also provides an information source
for care staff to make decisions about resident care.146,213
An in-depth ethnographic study of technology use in AL/RC reported that
staff are “overwhelmed by paperwork [...] they feel draws them away from focusing on
working with clients.”214 Perhaps most importantly, long-term care staff are underpaid
and under-resourced for the amount of care they are expected to provide to residents,
forcing staff to prioritize.215,216 It is possible that other tasks such as documentation and
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charting, though important, become a lower priority in an effort to meet the needs of
residents and perform caregiving tasks. Future studies could investigate whether and to
what extent regulations unintentionally incentivize documenting tasks at the expense of
person-centered care, and if any existing regulatory approaches strike a balance between
the two in the AL/RC context.
In addition to documentation errors, the way PRN medications are ordered place
direct care staff in a complicated position regarding the scope of their role regarding
medication administration. Regulations do not permit paraprofessional care staff to
evaluate or make decisions regarding treatments for residents and must deliver treatment
and medications as ordered by prescribers. The citations included in this study did not
capture the scenario of resident requests as they relate to PRN medications. Residents
may request certain as-needed medications from caregivers, who then decide whether to
facilitate the administration or not.141,172,203 In citations where the state agent listed
relevant medication orders for an individual resident, there was frequent co-prescription
of PRN antipsychotic and benzodiazepine medications. In some cases, a PRN
benzodiazepine was ordered for a resident’s “agitation” and a PRN antipsychotic order
was in place for “severe agitation.” Though direct care staff cannot formally assess or
evaluate residents, multiple medications orders and vague parameters put direct care staff
in a position where they can and do make these decisions in practice.
Unlicensed care staff may have a role in administering medications to
residents.140,193,217 Oregon’s Board of Nursing rules permit registered nurses to delegate
nursing tasks to unlicensed care staff.147,193,218 Presence of nurse delegation policies has
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been associated with a larger share of certified (as opposed to paraprofessional) staff
handling medication administrations.219 Nonspecific descriptions of behaviors assigned to
residents, combined with polypharmacy, increase the risk of medication administration
errors, most commonly consisting of documentation inconsistencies.143,194 Additionally,
unless an AL/RC setting is working directly with a consultant pharmacist or nurse,
pharmacy technician staff typically process prescription refills and communicate with
physician offices, presenting a potential barrier to oversight.220 Explicit study of
prescribing and deprescribing practices, assessment for inappropriate medications, staff
interpretation of prescriber parameters, and communication strategies among AL/RC staff
and prescribers are needed to more comprehensively understand how these citations are
associated with care delivery in these settings.221
Licensing regulations define psychotropic and PRN medication use in Oregon
AL/RC. In some states, like Alabama, AL/RC settings are not allowed to use
psychotropic medication to respond to residents’ behavioral symptoms under any
circumstances.222 Other states, such as Idaho, provide explicit guidelines for the
circumstances, conditions, and staff training related to psychotropic medication use.223
Disconnection between prescriber instructions, processes of care, and regulatory
expectations and enforcement have consequences. Studies that have examined the
relationship between regulatory oversight and use of antipsychotic medications suggest
public reporting and stringency do influence the rate these medications are used.224,225
Additionally, previous work has shown how the number and severity of deficiency
citations can indicate “quality,” though these reported relationships are nuanced and
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complex.184,188,189,192,226,227 Identifying AL/RC specific mechanisms for medication
prescription and administration is necessary to improve processes of care.27,28
3.5.1 Limitations & Future Directions
This study has several limitations. First, the level of detail documented in state
surveyor inspections facilitates or inhibits our ability to evaluate the qualitative context of
deficiency citations, beyond presence or absence. Future research could incorporate
interviews with surveyors, facility staff, and residents to contextualize and improve
understanding of quantitative and qualitative findings related to deficiency citations and
conceptualizations of quality and safety in long-term care. Second, this study examined
AL/RC regulatory requirements in a single state and may not apply to the regulatory and
practice environments of psychotropic medication use among AL/RC residents in other
states. Psychotropic medication use and regulatory requirements may differ based on the
licensing and classification within states. Variation in regulations and resident
populations among AL/RC settings across the U.S., merit comparison of psychotropic
medication use in AL/RC settings between and within states to inform relevant policy
action. Third, this study focused on psychotropic medication deficiency citations and
cannot speak to the greater context of organizational practices or compliance with
licensing regulations, which may relate to psychotropic medication use. Relatedly, the
extent to which AL/RC settings implement the proposed plans of correction or whether
these plans are effective at reducing deficiencies are not reflected in these data. Fourth,
examining psychotropic medication deficiency citations does not provide a
comprehensive perspective of nursing and direct care staff administration decision
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making. Understanding the context of these practices requires review of resident MARs
to assess the prevalence and frequency of psychotropic medication prescription and
administration within AL/RC settings.
3.5.2 Conclusions & Implications
Documentation errors comprised the majority of psychotropic medication
deficiency citations issued to Oregon AL/RC settings from 2015-2019. By examining
deficiency citations, policy makers, operators, and staff can identify (in)congruence
between regulatory expectation and practical reality. Policymakers can consider how
regulations may unintentionally incentivize task-oriented versus person-centered care
practices and incorporate AL/RC staff perspectives in policy development. Citations do
not fully capture the upstream circumstances that may lead to organizational
noncompliance including physician prescribing practices, staff resources and support, and
industry influences (eg, revenue, pharmaceutical culture, operationalization of behavioral
expressions associated with ADRD/cognitive impairment).
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Chapter 4: Antipsychotic Medication Use in Assisted Living/Residential Care: Do
Organizational Characteristics Matter?
4.1 Abstract
Objective: To investigate how the assisted living/residential care (AL/RC) and memory
care (MC) contexts are associated with the prevalence of antipsychotic medication use
(APU).
Data sources: Primary data were collected from a statewide representative sample of
AL/RC settings through the Oregon Community-Based Care study from 2017-2019 and
combined with publicly available administrative data.
Study Design: Framed by Donabedian’s model of care quality, we examine associations
among 90-day prevalence of APU, organizational, care process, and AL/RC resident
population characteristics using random intercepts regression models.
Data Collection: Every licensed AL/RC setting in Oregon receives an annual mailed
survey to provide aggregate resident demographics, health acuity, health service use,
payment type and organizational policies. Organizational measures (e.g., profit status,
license type, geographic designation) were collected from state websites.
Principal Findings: The average 90-day prevalence of APU among all Oregon AL/RC
settings is 30.7%, though rates differ by MC endorsement (23.9% in AL/RC and 42.7%
in MC). Compared to care processes and resident population characteristics,
organizational characteristics were associated with larger magnitudes of difference in
rates of APU. Nonprofit settings were associated with lower rates of APU in both AL/RC
(β= -4.4 (percentage points), [95% CI: -8.4, -0.4]) and MC (β= -12.4, [95% CI: -21.2, 3.6]. Compared to low-Medicaid settings, settings with very high proportions of
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Medicaid residents were associated with higher prevalence of APU, +8.9 in AL/RC (95%
CI: 1.7, 16.1) and +11.0 percentage points in MC (95% CI: 2.3, 19.8).
Conclusions: APU prevalence in MC settings is considerably higher than other longterm care options. Additional study is needed to contextualize the relationships between
AL/RC population-level practices and characteristics and the prevalence of APU to
inform policy and practice development related to this measure as a quality indicator.
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4.2 Introduction
Assisted living and residential care (AL/RC) settings are increasingly important
providers of long-term services and supports for older adults in the United States (U.S.),
outpacing nursing home (NH) availability.53,54 Approximately 29,000 AL/RC settings are
home to ~812,000 residents.1 One quarter of AL/RC settings report at least 75% of their
resident populations have an Alzheimer’s disease or related dementia (ADRD)
diagnosis.228 The estimated prevalence of persons living with ADRD ranges from 42 to
72% in these settings.1,2 Residents with cognitive support needs commonly express
behaviors, which can manifest as a means of communication, response to environmental
stimuli, or reaction to pain or discomfort.3,4,6,60,74 Behavioral expressions associated with
ADRD include agitation, wandering, sleep disturbances, hallucinations, and
delusions.5,7,8,59 These behaviors can result in considerable distress to the resident and
their family, and other residents and care staff.11,12,67–69,229
Residents’ quality of care and life can depend on appropriate understanding of
and responses to the underlying causes of behavioral expressions through a balance of
psychosocial and medication-related interventions.4,13,15,72,230 Common pharmaceutical
approaches to manage behaviors expressed by people living with ADRD include
psychotropic medications (ie, benzodiazepines, antipsychotics, sedatives, anxiolytics, and
antidepressants), though risks associated with these medications must be balanced with
potential benefits.16–18,77,81,131,231 Clinical practice guidelines recommend antipsychotic
medications, in particular, only for severe psychotic symptoms unresponsive to
nonpharmacologic treatment.77,232,233 Specifically for people living with ADRD,
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antipsychotic medication use (APU) has been associated with adverse outcomes
including falls, sedation, cognitive decline, and mortality.19–22,108,212,234,235
Much attention has been paid to reducing inappropriate APU in NH, though
people living with ADRD reside in various care settings that warrant similar
intervention.27,28,181 One recent study found higher prevalence of potentially inappropriate
APU in AL/RC settings compared to NH.23 Both the Centers for Medicare and Medicaid
Services (CMS) and industry organizations identify APU as a top priority in the context
of long-term care quality improvement, though explicit initiatives to reduce APU in older
adults with ADRD have largely focused on NH settings.25,26,102
Many characteristics should be considered in the context of quality
improvement. Researchers studying quality of life and quality of care in long term
supports and services conceptualize organizational characteristics such as ownership,
chain membership, size, occupancy, and Medicaid census as indicators of a settings’
ability to meet resident needs.236,237 Recent reviews have identified medication
management as a relevant quality domain pertaining to AL/RC settings, encompassing
APU.238,239 The prevalence of AL/RC residents living with ADRD and ongoing efforts to
improve quality of care warrant the investigation of APU as a quality indicator in relation
to other characteristics deemed relevant to quality measurement.
AL/RC settings offer different levels of care to meet the individual needs of
residents who live with complex health conditions, medication regimens, and often
receive assistance with activities of daily living. Almost two-thirds of residents receive
bathing assistance overall, ranging from 48% to 86% depending on the prevalence of
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dementia.1,228 Dementia care, or memory care (MC), units are licensed and marketed to
provide care for people living with ADRD. Each state regulates and oversees AL/RC
settings, determining licensing, resident admission/discharge, staffing levels, and
dementia care practices criteria, resulting in within and between state variation.111,112,197
Variation in populations served and practices enacted by different types of licensed
AL/RC settings warrants intrastate investigation. In Oregon, AL/RC settings operate
under the same regulations, but differ in the physical environment: AL settings must have
private bathrooms and kitchenettes, where RC settings may have shared bathrooms and
kitchens.122 Both AL/RC settings can have MC endorsements, catering to residents
diagnosed with ADRD and included additional dementia-specific training and staffing
requirements.123
4.2.1 Conceptual Model
This study employs Donabedian’s model of care quality. While this framework
was developed to assess quality of medical care delivery, it has been expanded upon and
applied to other health services and long-term care settings.239,240,240–244 Foundationally,
Donabedian’s model categorizes sources of information related to quality in healthcare
and health services in three areas: structures, processes, and outcomes. Structures
comprise the organizational characteristics of a health organization and are referred to as
“organizational” in this study. Processes encompass how providers and receivers of
health services interact, and outcomes are broadly considered as the individual health
statuses of those receiving health services.
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Figure 1. Application of Donabedian's model to antipsychotic medication use in assisted
living/residential care settings.

We apply Donabedian’s model to examine the relationships among proxy
measures for organizational characteristics and care processes associated with the
prevalence of APU in AL/RC populations (Figure 1). Care processes of interest include
medication administration, hospice service use, and assistance with behaviors. Regulatory
oversight of licensed care settings can facilitate or inhibit organizations’ abilities to
meet residents’ needs.114,245 While processes and practices within AL/RC settings are
theoretically driven by residents’ needs, the policy and regulatory environment shapes the
underlying structure of AL/RC settings via licensing and oversight. We explore the extent
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to which the residential/organizational context affects how organizational characteristics
and care processes are associated with the prevalence of APU.
4.3 Methods
4.3.1 Study Design and Sample
We conduct a secondary data analysis of the annual Oregon Community-Based
Care (CBC) Study of AL/RC settings operating in Oregon, where the AL/RC setting is
the unit of analysis.121,246,247 The study team mails paper surveys to all actively licensed
AL/RC settings in Oregon. Those who responded to the 2017-2019 waves of the CBC
study were included in this analysis. Not every setting participated in all three study
waves, resulting in an unbalanced panel (195 of settings participated in three waves, 171
in two waves, and 118 in one wave). All variables included in the analysis had less than
5% missing information. The final analytic sample includes 932 observations after
listwise deletion (11% reduction) from 463 (4% reduction) settings across 2017-2019
(137 of settings participated in all three waves, 195 in two waves, and 131 in one wave).
4.3.2 Data Sources
As explained above, this study utilizes three waves (2017-2019) of the Oregon
CBC study.121,246,247 which provides aggregate AL/RC setting-level characteristics. We
used publicly available DHS/APD rosters of currently licensed settings to source
organizational characteristics (e.g., licensed capacity, license type, Medicaid contract).204
We then matched settings’ zip codes to service area maps that designate urban and rural
geography.206 Finally, we used the most recent business filings on the Oregon Secretary
of State’s website to identify each settings’ registered owners’ profit status.207
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4.3.3 Measures
Outcome measure. AL/RC setting prevalence of APU, defined as the proportion
of residents within each setting who received antipsychotic medication in the past 90
days.
Organizational characteristics. Setting size, calculated using the highest number
of residents a settings are licensed to accommodate, was categorized as: small (7-24
beds), medium (25-49 beds), large (50-74 beds), and very large (75 or more beds).248
License type identifies the regulatory certification of the setting: AL/RC or MC.
Geographic designation and profit status are dichotomous measures: urban or
rural/frontier counties and for profit/nonprofit. Medicaid census categorically measures
the percent of residents using Medicaid to pay for services, divided into four categories
using thresholds based on quantile distributions: low (0% - 15%), moderate (15.1%–
43.1%), high (43.2%–67.7%), and very high (67.8%–100%).
Process characteristics. We use two measures as proxies for relevant care
processes within an AL/RC setting: percentage of residents who receive staff assistance
to take oral medications, and a constructed “behavioral needs index.” Receiving
medication assistance is associated with other functional assistance in addition to
caregiving time.249 The latter provides a measure of the prevalence of behavioral needs
across settings and is based on a count of residents who need regular and ongoing
assistance with each of three behavioral expressions: 1) lack of awareness of safety,
judgment, and decision making, or ability to orient to surroundings, 2) wandering, and 3)
danger to self or others. The behavioral needs index is constructed by adding together the
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percentage of residents needing assistance with the aforementioned behaviors divided by
the number of behaviors, resulting in a scale from 0 (no behavioral needs) to 100 (all
residents receive assistance with all three behavioral needs).
Covariates. Characteristics of settings’ resident populations will be used as
control measures within the regression models, based on findings from previous
studies.125,132,134,250 The average age of residents is reported in years. We also report
setting-level prevalence of residents by sex, race/ethnicity, diagnosed with ADRD or
serious mental illness, and those who used hospice services within the past 90 days. We
collected data on racial/ethnic categorization in this survey based on U.S federal
government standards: American Native/Alaska Native, Asian, Black/African American,
Hispanic/Latino, Native Hawaiian/Pacific Islander, White, or multiracial.251
4.3.4 Analytic Approach
We use means, standard deviations, and proportions to present summary statistics.
We employ multilevel models in this study, where survey waves are nested within
settings. First, we assessed bivariate associations between the dependent variable and
organizational, process, and covariate characteristics using unadjusted setting-level
random intercepts regression models stratified by license type (AL/RC vs. MC), and then
estimate setting-level random intercepts regression models to test associations of
organizational characteristics and proxy measures of care processes, adjusting for grouplevel covariates. Random intercepts regression is used to assess differences in the
prevalence of APU within and between individual settings over time, accounting for
AL/RC settings that consistently have higher or lower prevalence of APU compared to
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others in the sample. To account for repeated measures from each setting over time, study
waves are clustered within settings to ensure robust standard errors and appropriate
estimates.252 All analyses were conducted using Stata 15.253
4.4 Results
4.4.1 Summary Statistics
Table 1 describes the organizational, care processes, and resident population
characteristics of the responding AL/RC settings for 2017-2019 CBC study waves and by
license type. Settings ranged in size from seven beds to 186 beds with a median of 48
beds. Most settings operated for profit and in urban counties. A larger share of
responding MC settings operate for profit and in urban counties compared to AL/RC only
settings. The average proportion of residents using Medicaid to primarily pay for services
is 42.3% across all license types. A slightly larger share of MC settings (26.6%) were
categorized as very high Medicaid compared to AL/RC settings (23.6%). Bolded pvalues beside characteristics indicate significant differences at p < .05 between MC and
non-MC cases based on t-tests and Pearson's chi-square tests.
Similar to national estimates, residents in our study are mostly female, nonHispanic White, and over 80 years old.1 The average proportion of residents diagnosed
with ADRD was 54.6% (median: 43.0%) and the average proportion of residents
diagnosed with serious mental illness was 8.1% (median: 4.0%). The average proportion
of residents receiving regular and ongoing assistance with taking oral medications were
81.9% (median: 95%). The average prevalence of APU in the last 90 days was 30.7%
(median: 22.2%). MC settings had larger average proportions across all care process
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characteristics. The average proportion of residents receiving hospice care or
antipsychotic medications in the last 90 days were also higher in MC settings. AL/RC
settings had a larger average proportion of residents with a diagnosis of SMI, though
across all settings the average SMI prevalence was below 10%.
Table 1. Proportions, means, and standard deviations of responding assisted
living/residential care and memory care setting characteristics, 2017-2019.
AL/RC
(n= 598)

Any MCa
(n=334)

Overall
(n=932)

21.7

33.5

26.0

Medium; 25-49 beds

26.1

32.6

28.4

Large; 50-74 beds

28.1

22.5

26.1

Very large; 75+ beds

24.1

11.4

19.5

54.8

59.6

56.6

45.2

40.4

43.4

Ownership: Nonprofit

14.1

8.1

11.9

For profit

85.9

91.9

88.1

27.9

19.8

25.0

Moderate (15.1%–43.1%)

24.7

25.1

24.9

High (43.2%–67.7%)

23.7

28.4

25.4

Very high (67.8%–100%)

23.6

26.6

24.7

Characteristics
Organizational (%)
Size: Small; 0-24 beds

Geographic Designation: Urban
Rural/frontier

Medicaid census: Low (0–15%)

pvalue

0.000

0.162
0.007

0.040

Care Processes (mean (SD))
% residents receiving assistance with:
Taking oral medications

75.8 (30.0) 92.7 (22.3) 81.8 (28.7) 0.000

Behavioral needs index (0-100)

11.2 (14.7) 39.3 (17.8) 21.2 (20.8) 0.000

Lack of awareness of safety

23.7 (29.3) 79.7 (29.2) 43.8 (39.7) 0.000

Wandering

5.0 (10.2) 29.3 (28.2) 13.6 (22.0) 0.000

Danger to self/others

4.8 (14.3)

8.9 (14.4)

6.3 (14.5) 0.000

81.8 (7.7)

83.2 (5.3)

82.3 (7.0) 0.002

Resident Population (mean (SD))
Average age (years)
% of residents:
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Female

68.0 (14.4) 71 (13.0) 69.0 (14.0) 0.005

Male

32.0 (14.4) 28.3 (13.0) 31.0 (14.0) 0.005

Hispanic or Latino and/or persons of color 5.2 (11.0)

7.1 (13.6)

5.6 (12.1) 0.124

Hispanic or Latino, any race

1.1 (2.5)

1.8 (3.3)

1.3 (2.9)

0.000

American Indian/Alaska Native

1.0 (3.9)

1.3 (7.9)

1.1 (5.7)

0.497

Asian

0.8 (2.2)

1.2 (2.3)

1.0 (2.3)

0.007

Black/African American

0.8 (4.6)

1.0 (3.2)

0.9 (4.2)

0.460

Native Hawaiian/Pacific Islander

0.6 (5.9)

0.5 (5.3)

0.6 (5.7)

0.753

Multiracial

0.8 (5.5)

1.2 (7.6)

0.9 (6.4)

0.386

non-Hispanic/Latino, White

90.0 (21.7) 87.6 (24.5) 89.2 (22.8) 0.124

Race/ethnicity not disclosed

4.8 (19.2)

5.3 (21.7)

5.0 (20.1)

Alzheimer’s or related dementia diagnosis 33.9 (24.0) 91.7 (19.6) 54.6 (35.7) 0.000
(ADRD)
Serious mental illness (SMI) diagnosis

9.0 (17.2)

6.5 (10.3)

8.1 (15.1) 0.017

Receiving hospice services (last 90 days)

6.7 (8.8)

11.0 (9.5)

8.2 (9.3)

0.000

Using Medicaid to primarily pay for
services

40.5 (31.5) 45.4 (29.5) 42.3 (30.9) 0.021

Receiving antipsychotic medication (last
90 days)

23.9 (23.7) 42.7 (23.5) 30.7 (25.3) 0.000

a“Any

memory care” includes settings where MC units are co-located within assisted living/residential care settings as
opposed to stand-alone MC settings.

4.4.2 Random Intercepts Regression of Organizational Characteristics
Figure 2 shows the coefficient estimates and 95% confidence intervals for four
random intercepts regression models estimating associations among organizational and
the prevalence of APU in the prior 90 days, stratified by license type. Bivariate and
adjusted model estimates and 95% CIs are located in more detail in Appendix A, Table 2
and Table 3.

57
Figure 2. Results from random intercepts regression analysis of organizational
characteristics and prevalence of antipsychotic medication use by setting type, 20172019.

* p < 0.05, ** p < 0.01, *** p < 0.001
a
“Any MC” includes memory care units that are co-located within assisted living or residential care settings.
b
Over the study period, AL/RC settings comprise 598 observations clustered within 297 settings and MC settings comprise 334
observations clustered within 167 settings.

In bivariate analysis, settings with larger Medicaid censuses were associated with
higher prevalence of APU across all setting types (Table 2). Larger AL/RC settings (β= 27.3 (percentage points), [95% CI: -35.3, -19.3] and nonprofit MC settings (β= -13.0
(percentage points), [95% CI: -23.3, -2.7]) were associated with lower prevalence of
APU. AL/RC setting size and nonprofit MC status remain negatively associated and
larger Medicaid census across all settings remain associated with higher prevalence of
APU when adjusting for all organizational characteristics (Figure 2, Table 3). Medicaid
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census and setting size appear to show a linear relationship (positive and negative,
respectively) with the prevalence of APU among AL/RC settings, but not in MC settings.
4.4.3 Random Intercepts Regression of Processes of Care and Resident Population
Characteristics
Figure 3 shows the coefficient estimates and 95% confidence intervals for random
intercepts regression models estimating associations among measures of care processes
and resident population characteristics and the prevalence of APU in the prior 90 days,
stratified by license type (Table 2 and Table 3). In bivariate analysis, higher average age
and proportions of residents who were female were associated with lower APU
prevalence in AL/RC settings while proportions of residents diagnosed with ADRD and
SMI, and greater behavioral needs were associated with higher APU prevalence. In MC
settings, only the proportion of residents receiving assistance taking oral medications was
associated with the prevalence of APU (Table 2). Including all processes of care
measures and resident characteristics attenuates the relationship between proportion of
female residents and APU, though reflect bivariate associations with other characteristics
among AL/RC settings. A one percentage point increase in the proportion of residents
with ADRD is associated with a 0.2 percentage point increase in the prevalence of APU,
even when adjusting for the proportion of residents diagnosed with SMI (Figure 3, Table
3). In the adjusted model, an increase in the proportion of residents using hospice in the
prior 90 days has the same effect on the prevalence of APU in both AL/RC and MC
settings.
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Figure 3. Results of random intercepts regression analysis of processes of care and
resident population characteristics and prevalence of antipsychotic medication use by
setting type, 2017-2019.

* p < 0.05, ** p < 0.01, *** p < 0.001
a “Any MC” includes memory care units that are co-located within assisted living or residential care settings. Because
residents living in memory care must have an Alzheimer’s or related dementia diagnosis, the “any MC” model excludes
ADRD due to collinearity.
b Over the study period, AL/RC settings comprise 598 observations clustered within 297 settings and MC settings
comprise 334 observations clustered within 167 settings.
c “POC”= people of color; Includes residents identified as American Indian/Alaska Native, Asian, Black/African
American, Native Hawaiian/Pacific Islander, and multi-racial
d Behavioral needs index = [(% residents receiving assistance for lack of awareness to safety + % wandering + %
danger to self/others) / 3] x 100

4.4.4 Fully Adjusted Random Intercepts Regression Model
Figure 4 shows coefficient estimates and 95% CIs for the fully adjusted models
(including all organizational, care processes, and resident characteristics stratified by
license type (also see Table 4). Overall, the relationships examined in the models only
controlling for organizational or care processes and resident population characteristics are
replicated in the models controlling for all sets of characteristics.
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Figure 4. Results of random intercepts regression analysis of organizational, processes of
care and resident population characteristics and prevalence of antipsychotic medication
use by setting type, 2017-2019.

* p < 0.05, ** p < 0.01, *** p < 0.001
a
“Any MC” includes memory care units that are co-located within assisted living or residential care settings. Because residents living
in memory care must have an Alzheimer’s or related dementia diagnosis, the “any MC” model excludes ADRD due to collinearity.
b
Over the study period, AL/RC settings comprise 598 observations clustered within 297 settings and MC settings comprise 334
observations clustered within 167 settings.
c
“POC”= people of color; Includes residents identified as American Indian/Alaska Native, Asian, Black/African American, Native
Hawaiian/Pacific Islander, and multi-racial
d
Behavioral needs index = [(% residents receiving assistance for lack of awareness to safety + % wandering + % danger to self/others)
/ 3] x 100

Although the effect size has slightly decreased, measures of size and Medicaid
census have similar linear relationships with the prevalence of APU among AL/RC
settings compared to bivariate and adjusted models presented Figure 2, Table 2, and
Table 3. MC settings do not reflect this linear relationship. Nonprofit status is associated
with lower prevalence of antipsychotic use across all settings, though there is a larger
effect size for MC settings. Our measure of behavioral needs within MC resident
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populations is not significantly associated with prevalence of APU in any model
estimation presented in this study, though it is associated in AL/RC populations.
4.5 Discussion
This study utilized three years of facility-level panel data to estimate associations
between measures of organizational, processes of care, and resident population
characteristics with the average 90-day prevalence of APU among AL/RC and MC
settings in Oregon. From 2017-2019, the average 90-day prevalence of antipsychotic use
across all setting types was 31%. APU rates differed by license type: 24% in AL/RC and
43% in any setting with MC certification. Characteristics associated with differences in
average 90-day prevalence of APU include size, profit status, Medicaid census,
prevalence of ADRD, serious mental illness, assistance with oral medications, hospice
use, and behavioral needs. Despite accounting for characteristics of the resident
population, organizational characteristics remained associated with APU rates compared,
and license types moderated the patterns of association among these characteristics. This
study contributes a representative, statewide, longitudinal analysis of APU in AL/RC
settings and resident populations. APU is important because of its prevalence in people
living with ADRD, despite associations with adverse outcomes.20,22,23,212,232
We found that the APU prevalence in MC settings (43%) is greater than other
long-term care options in Oregon: AL/RC settings (24%), adult foster homes (35%),254
and NHs (15%).124 MC residency is conditioned upon a diagnosis of ADRD, and this
diagnosis is associated with a higher likelihood of receiving antipsychotic medications.255
ADRD prevalence in Oregon differs by setting type: 34% in AL/RC and 92% in any MC
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setting, compared to 46% in adult foster homes254 and 18% in NHs.124 Additionally, our
prior work showed that individual residents living in MC settings were twice as likely to
receive an antipsychotic medication in the prior 90 days compared to AL/RC residents.134
We observed a mix of organizational, care processes, and resident population
characteristics associated with the average 90-day prevalence of APU. AL/RC resident
populations that have greater behavioral needs and prevalence of serious mental illness
had higher average prevalence of APU, but not in MC settings. In MC settings, a higher
proportion of residents receiving staff assistance with taking oral medications was
associated with higher prevalence of APU. As expected, hospice use prevalence was
associated with higher prevalence of APU across setting types.
Organizational characteristics are associated with average prevalence of APU
regardless of care processes and resident population characteristics. In particular,
nonprofit status was consistently associated with lower prevalence of APU and Medicaid
census was consistently associated with higher prevalence of APU across setting types.
Among AL/RC settings, we observed a linear relationship when comparing the
prevalence of APU in the very high Medicaid settings compared to low Medicaid settings
(ie, greater percentage of private pay residents). While Medicaid census was also
associated with higher APU in MC settings, we did not observe the same linear
relationship. At the individual level, receiving an antipsychotic medication in the last 90day period was not associated with a resident’s use of Medicaid.134 Other studies have
reported NH residents primarily using Medicaid were more likely to have inappropriate
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APU than private pay residents256 and, similar to our findings, settings with high
Medicaid census reported higher APU.257
Donabedian’s model asserts that a combination of organizational and process
characteristics facilitates outcomes used to conceptualize quality. Our finding that
settings with higher proportions of residents primarily using Medicaid (based on quartile
distributions) have higher prevalence of APU warrants further consideration. Over time,
Medicaid has increased as a payment source for home and community based care settings
through state waiver programs, though most utilizers are people with intellectual and
developmental disabilities (63%) compared to older adults and people with physical
disabilities (41%).258 Nationwide, an estimated 48% of AL/RC communities report
Medicaid-certification, with only 17% of residents primarily using Medicaid to pay for
services nationally.1 On average, 42% of Oregon AL/RC residents primarily used
Medicaid to pay for services.121
Higher Medicaid reimbursement rates have been associated with improved quality
measures and resident outcomes among NH residents, including increased continuity of
care, staffing levels, and lower hospitalizations, incidence of pressure ulcers, restraint use
and APU.102,259–261 In Oregon, the 2018 monthly Medicaid reimbursement rate for an AL
resident ranged from $1,234 (receiving the lowest level of care) to $2,922 (receiving the
highest level of care) and $4,063 for MC residents.262 On average, private pay AL and
MC residents in Oregon pay an estimated $3,959 and $5,620 per month receiving the
lowest level of care, respectively.263 Additionally, Medicaid does not reimburse for room
and board costs in AL/RC.264 Settings with a high proportion of Medicaid residents
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operate with less financial resources than settings with high proportions of private pay
residents, potentially impacting operations with regard to staff time, and ability to meet
residents’ needs.265 For example, from NH research indicate a pattern of residents who
primarily use Medicaid are clustered in lower quality facilities.266
In Oregon, RC settings, which differ from AL in terms of resident population,
size, and physical environment, are more likely to have MC endorsements as well as
more likely to accept Medicaid residents compared to AL settings,267 which may also
partly explain the observed association between APU prevalence and a setting’s
Medicaid census. Over time, the number of settings with MC certification increased from
148 in 2014 to 186 in 2019, (26% increase over five years). Nationally, an increased
supply of AL availability is associated with a decrease in residents who have lower care
needs, but qualify for NH, where Medicaid is more widely used.54,119 However,
Medicaid-eligible AL/RC residents tend to have greater needs, higher levels of chronic
care conditions, and disability.268 Additional time points, accounting for staff levels,
composition, and training, in addition to AL/RC residents’ health- and care-related needs
are necessary to further disentangle the relationship between prevalence of APU and
proportion of residents using Medicaid. A future study could examine whether increases
in MC availability correlate to increases in proportions of Medicaid residents served in
AL/RC settings.
In the last decade, there has been an organized effort to reduce off-label APU in
NH, incentivized through a direct connection to public-facing quality indicators in these
settings, such as 5-star rankings.102,225 AHCA/NCAL (2020) has a quality initiative
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encouraging AL/RC settings to reduce the rate of off-label APU to 15%, mirroring
similar efforts in NH.26 Similarly, Oregon’s 2017 legislative session passed two bills
regarding AL/RC quality of care, one to reduce medication errors136 and the other reduce
adverse side effects and nonstandard long-term use of antipsychotic medications.39
Policymakers might consider potential differential impact by using APU prevalence as a
quality indicator. Given the heterogeneous structure of AL/RC regulations, organizational
resource capacity, and care needs among resident populations, a pre-set threshold of APU
does not explicitly address appropriate vs. inappropriate use. At the population level, this
measure may represent a setting’s resource decision making and capacity to respond to
the needs of people living with ADRD, as evidenced by settings with higher proportions
of Medicaid residents associated with higher APU. State agencies can address the
association of APU with organizational resources and (in)appropriate medication use as
two different, though related, concerns.
AL/RC, as conceptualized, is a residential setting meant to support residents with
health-related services and social engagement.116 Qualitative study and intentional
collaboration with AL/RC residents, care staff, operators, and care coordinators (external
or onsite) is needed to contextualize how AL/RC settings adapt to both the dynamic
needs of their resident populations and resources required to meet those needs. Additional
inter- and intrastate comparison of characteristics associated with APU, such as
accounting for organizations that operate within and across state lines (ie, chains), could
further elucidate how regulatory classifications and organizational characteristics impact
delivery of quality care to AL/RC resident populations.
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4.5.1 Limitations & Future Directions
Though we examined data from 2017-2019 waves of the Oregon CBC study in
this analysis, the associations reported necessitate additional data points for more precise
estimates. The restricted focus of relevant structural characteristics related to care
processes and outcomes on material and organizational conditions, and the lack of
attention to the power structures that fundamentally dictate organizational characteristics,
care processes, and outcomes of interest presents another limitation.269,270 Power
structures take many forms, including interpersonal (eg, residents and care staff, care
staff and supervisors, facility staff and corporate management), organizational (eg,
AL/RC settings, profit status, interaction with state agencies), socioeconomic (eg, access
to additional services and primary care, ability to pay staff a living wage, pharmaceutical
production and distribution), and structural (eg, capitalism, ableism, ageism, racism). For
example, recent evidence also suggests increases in the prevalence of serious mental
illness (eg, schizophrenia) in long-term care settings,271 conditions indicated for treatment
with antipsychotic medications. However, a troubling trend is emerging where incident
schizophrenia diagnoses in long-term care residents living with ADRD are increasing
overall, with disproportionately higher rates among Black nursing home residents living
with ADRD.272
Despite existing frameworks and best intentions, care quality conceptualization
and measurement remains a social construct dependent on the social and political capital
of those who decide upon the assessment criteria.273,274 Investigating how power
dynamics influence decision making at interpersonal and systemic levels related to
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AL/RC residents’ care would greatly strengthen future studies of long-term care
populations.
The outcome measure—as operationalized in this study—does not fully capture
the theoretical construct of APU, which encompasses several phenomena, including
prescription, administration, production, and distribution. Prescription is the act of a
prescriber (eg, medical doctor, nurse practitioner) writing an order for a medication as
treatment for a condition. Prescriptions can be ordered on a scheduled or pro re nata
(PRN; as needed) basis depending on the type of medication and the condition being
treated. Administration describes the act of taking or being given medication. For staff to
administer medications to residents, a prescription order is necessary. The presence of a
prescription order, especially for PRN medications, does not necessarily equate to the
administration of a medication.141 We only know the number of residents who received
antipsychotic medication in the prior 90 days, not how many times an antipsychotic
medication was administered nor the reasons for administration. Further upstream, the
popularity of APU, particularly off-label use, is partially rooted in the costs and revenue
associated with the production, distribution, and profit of these medications.17,275,276
External societal and economic environments frame the context of prescription and
administration patterns, and warrant further study in the older adult population. While
prevalence of APU is considered a quality metric in both nursing homes and assisted
living, additional perspectives are needed to more holistically understand AL/RC
settings’ abilities to respond to residents’ behavioral expressions, in addition to reducing
the use of potentially inappropriate medications.
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4.5.2 Conclusions & Implications
In Oregon, the 90-day prevalence of APU across licensed AL/RC settings is
notably higher than what quality metrics would suggest is appropriate. Given state
variation in AL/RC regulation and oversight, understanding whether certain
characteristics of AL/RC settings are associated with higher or lower prevalence of APU
can inform policy and practice development related to treating APU as a quality
indicator. Policymakers, long-term care advocates, and AL/RC organizations might
consider how organizational resource capacity and meeting the needs of resident
populations influence APU in AL/RC settings, especially if APU prevalence is treated as
a quality indicator. Further understanding of medication administration and prescription
decision making is necessary to contextualize reported rates of APU.
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Appendix A. Supplemental Tables
Table 2. Bivariate random intercepts regressions of organizational, process, and resident
population characteristics associated with prevalence of antipsychotic use by setting type,
2017-2019
Any MCa
β [95% CI]

AL/RC
β [95% CI]
Survey Wave (ref. 2015-2016)
2017-2018
2018-2019
Size (ref. <25 beds)
25-49 beds
50-74 beds
≥75 beds
Rural/Frontier (ref. Urban)
Nonprofit (ref. For profit)
Medicaid census (ref. Low)
Moderate
High
Very high
Average age (years)
Proportion of residents:
Female
Hispanic/Latino and/or POCb
Diagnosed with ADRDc
Diagnosed with SMIc
Assist w/ oral medications
Use hospice services (prior 90
days)
Behavioral needs indexd
N (cluster)
*

-1.6
-0.8

[-4.8, 1.]
[-2.6, -4.1]

-4.1
-2.4

[-10.0, 1.8]
[-9.0, 4.1]

18.3***
21.1***
25.0***
-0.6
-4.9

[-27.5, -9.1]

0.4

[-6.9, 7.6]

[-29.5, 12.6]
[-33.2, 16.7]
[-5.6, 4.3]
[-11.3, 1.5]

-0.4

[-7.3, 6.5]

-2.8

[-15.4, 9.7]

-0.3
[-6.1, 5.6]
**
-16.4
[-25.9, -7.0]

0.0
6.4*
13.1***
-1.0***

[-5.1, 5.2]
[1.5, 11.2]
[6.6, 19.7]
[-1.3, -0.6]

11.9**
13.6***
13.4**
-0.5

[4.8, 19.0]
[7.2, 20.0]
[5.6, 21.2]
[-1.1, 0.2]

-0.3**
-0.0
0.2***
0.7***
0.0
0.3*

[-0.5, -0.1]
[-0.1, 0.1]
[0.1, 0.3]
[0.5, 0.8]
[-0.0, 0.1]
[0.1, 0.6]

-0.2
0.1
0.2
0.2***
0.3

[-0.4, 0.0]
[-0.1, 0.3]
[-0.1, 0.5]
[0.1, 0.3]
[-0.0, 0.7]

0.6***
[0.5, 0.8]
598 (297)

0.1

[-0.0, 0.3]
334 (167)

p < 0.05, ** p < 0.01, *** p < 0.001
“Any MC” includes memory care units that are co-located within assisted living or residential care
settings. Because residents living in memory care must have an Alzheimer’s or related dementia diagnosis,
the any MC model excludes ADRD due to collinearity.
b
“POC”= people of color; Includes American Indian/Alaska Native, Asian, Black/African American,
Native Hawaiian/Pacific Islander, and multi-racial
c
ADRD= Alzheimer’s and related dementias; SMI-= serious mental illness
d
Behavioral needs index = [(% residents receiving assistance for lack of awareness to safety + %
wandering + % danger to self/others) / 3] x 100
a

Table 3. Results of random intercepts regression of organizational, care processes, and resident population
characteristics over prevalence of antipsychotic use, by setting type, 2017-2019
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Table 4. Results of fully adjusted random intercepts regression models of organizational,
care processes, and resident population characteristics over prevalence of antipsychotic
use by setting type, 2017-2019.
Any MCa
β [95% CI]

AL/RC
β [95% CI]
Survey year (ref. 2017)
2018
2019
Size (ref. <25 beds)
25-49 beds
50-74 beds
75+ beds
Rural/Frontier (ref. Urban)

[-3.4, 3.0]

-3.4

[-9.2, 2.4]

2.0

[-1.4, 5.3]

-2.7

[-9.2, 3.7]

-5.8

[-11.9, 0.4]

-2.4

[-9.3, 4.4]

-6.0
-9.3**

[-12.2, 0.2]
[-15.8, -2.7]

-6.5
0.1

[-13.3, 0.2]
[-10.3, 10.4]

-1.6

[-5.6, 2.3]

-4.0

[-9.8, 1.9]

*

Nonprofit (ref. For Profit)
Medicaid census (ref. Low)
Moderate

**

-4.4

[-8.4, -0.4]

-12.4

1.8

[-2.7, 6.3]

11.4***

[4.6, 18.2]

High

5.4

*

[0.4, 10.5]

***

[5.9, 19.7]

Very high

8.9*

[1.7, 16.1]

11.0*

[2.3, 19.8]

-0.3

[-0.6, 0.0]

-0.1

[-0.7, 0.4]

0.0

[-0.1, 0.2]

-0.2

[-0.4, 0.0]

-0.1

[-0.1, 0.0]

0.0

[-0.2, 0.2]

0.2***

[0.1, 0.3]

-

-

***

0.5
0.0

[0.3, 0.6]
[-0.0, 0.0]

0.1
0.2***

[-0.2, 0.4]
[0.1, 0.3]

0.3*

[0.1, 0.6]

0.3*

[0.0, 0.6]

*

[0.0, 0.4]
598 (297)

0.1

[-0.0, 0.3]
334 (167)

Average Age (years)
Proportion of residents:
Female
Hispanic/Latino and/or POC

b

Diagnosed with ADRDc
c

Diagnosed with SMI
Assist w/ oral meds

Using hospice (prior 90 days)
Behavior needs index
N (cluster)
*

-0.2

d

0.2

12.8

[-21.2, -3.6]

p < 0.05, ** p < 0.01, *** p < 0.001
“Any MC” includes memory care units that are co-located within assisted living or residential care settings.
Because residents living in memory care must have an Alzheimer’s or related dementia diagnosis, the any MC model
excludes ADRD due to collinearity.
b “POC”= people of color; Includes American Indian/Alaska Native, Asian, Black/African American, Native
Hawaiian/Pacific Islander, and multi-racial
c ADRD- Alzheimer’s and related dementias; SMI- serious mental illness
d Behavioral needs index = [(% residents receiving assistance for lack of awareness to safety + % wandering + %
danger to self/others) / 3] x 100
a
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Chapter 5: Beyond the Medication Pass: Attitudes, Ethics, Agency, and Antipsychotic
Medications in Assisted Living/Residential Care
5.1 Abstract
Background: Pro re nata antipsychotic medication use (PRN APU) among assisted
living/residential care (AL/RC) residents is a controversial health policy issue. AL/RC
care providers, families, clinicians, researchers, and policymakers disagree about using
these medications on an as-needed basis to manage behavioral expressions associated
with residents’ dementia or cognitive impairment.
Methods: Semi-structured interviews among 11 caregivers, medication technicians,
nurses, administrators/executive directors, and consultant pharmacists currently working
in Oregon AL/RC settings. I use situational analysis, an extension of grounded theory
methods, to identify and describe positions and ideologies related to APU.
Findings: Situational analysis facilitated identification of three main themes. First,
attitudes (ie, positive, neutral, and negative) inform whether to use PRN antipsychotic
medications. Second, an underlying morality and positioning of PRN antipsychotics or
nonpharmacologic interventions as “right” or “wrong” drive approaches to behavioral
response. Finally, I found an inverse relationship between the perceived level of agency
within and proximity to the situation of APU.
Conclusions: Participants described costs/benefits associated with PRN APU and
nonpharmacologic interventions when responding to AL/RC residents’ behavioral
expressions Understanding the scope and context of APU within AL/RC settings
necessitates a broader systems-level approach to this issue.
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5.2 Introduction
Assisted living and residential care (AL/RC) is a fast-growing segment of the
long-term services and supports sector in the United States (U.S.).52–54 Of the estimated
812,000 AL/RC residents in the U.S., 42% have been diagnosed with Alzheimer’s
disease or related dementias (ADRD).1 Over 70% of AL/RC residents living with ADRD
or cognitive impairment experience behavioral expressions.2 Behavioral expressions can
include aggression, agitation, anxiety, delusions, hallucinations, and sleeplessness.5,8,57,59
Chronic or severe behavioral expressions have implications for residents’ quality of life,
family and caregiver burden, and care transitions.67,69,70,229,277
Nonpharmacologic and pharmaceutical interventions describe the two
overarching approaches to responding to behavioral expressions. Existing guidelines and
practices encourage psychosocial or environmental interventions as the first line of
treatment in managing behavioral expressions as a person-centered, safe, alternative to
medication.15,44,72,77,131,278 When nonpharmacologic interventions fail or a resident is in
considerable, persistent distress, pharmaceutical management of behaviors using
psychotropic medication may be appropriate.77 Psychotropic medications interact with
the central nervous system and include the following drug classes: antipsychotics,
antidepressants, anxiolytics, hypnotics, and mood stabilizers.79,279
Though every psychotropic medication class is associated with significant risks in
older adult populations,16,81,88,108,109,234,280,281 antipsychotic medications have received
explicit empirical and regulatory attention. In the early 2000s, studies demonstrated that
off-label use of antipsychotic medications in older adults with dementia was associated

74
with a higher risk of early mortality,19,20 leading the U.S. Food and Drug Administration
to issue a “black box” warning on antipsychotic medication use (APU) in older adults.93–
95

Given the prevalence of older adults living with dementia in long-term residential care

settings, the Centers for Medicaid and Medicare Services developed quality improvement
efforts related to the use of these medications, forming the National Partnership for
Quality Dementia Care,25,104 which has been associated with reductions in antipsychotic
medication use in NH populations over time.102,103,182,282 There is still lack of evidence
regarding how antipsychotic medications are used, staff training and implementation of
nonpharmacologic interventions, uptake of other psychotropic medications beyond
antipsychotics, or potential discrimination against older adults whose behaviors are
deemed “challenging” within the AL/RC context.
There are many reasons antipsychotic medications are prescribed and
administered to older adults living with ADRD, primarily due to behavioral expressions
labelled as agitation and aggression.10,283 Clinicians, caregivers, and family members
reportedly view APU as positive, safe, and effective,29,30,101,284 though much of the
existing literature only focuses on NH residents and staff. One qualitative study detailed
how primary care providers primarily view pharmaceutical response to behavioral
expressions associated with ADRD as less risky than empirical evidence suggests and
that while policies do successfully decrease APU, they unintentionally promote other,
riskier medications.30 The same study team found direct care staff and family caregivers
in nursing homes described significant systemic and interpersonal barriers to performing
nonpharmacologic interventions compared to the effectiveness of medications.29 Other
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literature has shown the paradox faced by caregivers regarding APU, recognizing that
these medications are prescribed too frequently but can be the best of not ideal responses
when working with older adults living with ADRD.99
Key factors that influence decision making around APU in nursing homes include
organizational capacity, individual professional capability, communication and
collaboration, attitudes, and regulations/guidelines.285 In comparison to routine/scheduled
use of these medications, pro re nata (PRN; as needed) medication orders to respond to
behavioral expressions presents an additional layer of complexity and decision making,
especially for direct care staff who are not permitted to formally assess residents’
needs.78,141,199,286,287
Direct care staff (eg, caregivers, certified nursing assistants, and medication
aides) build and maintain relationships with their residents, learning from and basing
their care decisions on residents’ cognitive, physical, and emotional cues on a daily
basis.141,142,202,203 For those staff that assist with medications administered “as-needed,”
knowing individual residents’ behaviors and nuances is critical to decision making
around administration.139,142,143 Direct care staff may view behavioral and psychological
expressions of dementia negatively,12 and have several strategies to address these
behaviors, such redirection, isolation, seeking other coworkers’ assistance, or
communicated with external care providers.14,148,288 AL/RC care models that prioritize
autonomy, choice, dignity, independence, individuality, and privacy introduce another
component to the equation of medication management and APU.171,172,289 Balancing these
espoused values (eg, autonomy) with the constraints of the care situation (eg, safety) can
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result in multiple sources and levels of conflict regarding an “appropriate response” to
residents’ behavioral expressions and medication needs.172,203,290–293
Antipsychotic medication prescription and administration in AL/RC settings is an
under-studied and controversial community health and policy issue. Little is known about
direct care staff and nurse’s decision making and task-related responses to these
behaviors. In this study, I explore decision making related to administering PRN
antipsychotic medications among frontline AL/RC staff: caregivers, nurses,
administrators, and consultant pharmacists.
5.3 Methods
5.3.1 Sampling and Recruitment
A complete list of currently licensed AL/RC providers is publicly available
through the state Department of Human Services website.204 Using this list, I selected
facilities to contact using a random number generator until 25 administrators were
identified. I then individually emailed a flyer explaining the purpose of my study and
asking administrators to both participate in interviews and disseminate the flyer to their
staff and coworkers (Appendix B). This flyer contained a link and QR code where
individuals were provided with a digital consent form and could schedule a 30-minute
interview with me on their own schedule. In addition to scheduling the interview, I asked
participants to provide demographic information including their age, gender,
race/ethnicity, and job title (Appendix C). Every seven to ten days I again emailed those
who had not responded and repeated this process until enough participants responded to
capture diverse experiences related to PRN APU. I offered participants a $20 Amazon

77
gift card for participating, with financial support from a private donor to the Portland
State University Foundation for students studying gerontology. This study was approved
by Portland State’s Institutional Review Board (protocol #: 206858-18).
5.3.2 Data Collection
Participants scheduled an interview time on their own providing me with their
preferred method of contact, interviews took place over the phone and recorded and
transcribed over Zoom. Participants provided additional, verbal consent to recording and
then proceeded with the interview. I used a semi-structured interview approach, where I
had an initial question bank (Appendix D). I began every interview with an introduction
of the scope of the conversation and began with the following questions:
1) Please describe your job and what your responsibilities are.
2) Thinking about residents who have lived in this community who express
behaviors, can you tell me about a time when one of those residents was helped
through successful management by you and other staff?
3) How about a resident whose behavioral expressions were so severe that you or
your staff were not able to respond, can you tell me that story?
I based the scenario questions (2 and 3) on a recent study examining staff reports of
residents’ behavioral expressions in AL/RC settings.10 How a participant described their
roles and responsibilities guided which questions I followed up with from the available
question bank. For example, a medication aide described medication passing as one of
their roles, which led me to ask about their experiencing administering PRN
antipsychotic medications. However, if an unlicensed caregiver indicated they did not
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have a role in medication administration, I did not ask about administering medications.
The experiences participants chose to share also facilitated additional probes and follow
up questions that arose within the interview.
Before closing the interview, I also asked every participant to share how a
hypothetical policy would potentially affect their work. Specifically, “Hypothetically, if
the state were to introduce a requirement that no more than 20% of assisted living,
residential care, and memory care residents could have a PRN antipsychotic medication
order, how would that affect your work?” I derived this question from existing guidelines
for nursing home settings,104 and proposed quality goals for AL/RC settings.26 After
downloading the recordings and transcripts to a secure cloud-based server, I listened to
each recorded interview to ensure transcription accuracy.
5.3.3 Data Analysis
I used grounded theory methods for analyzing qualitative data.160,163–165,174 I read
through each transcript and took notes on topics and patterns I noticed arising in each
conversation. These formed the initial foundation of codes to describe PRN antipsychotic
medication administration. I developed a preliminary set of a priori codes based on the
interviewing experience and elements of situational analysis to orient myself to the data.
General categories for codes included roles (eg, people, positions, jobs identified as
involved), attitudes (eg, emotions, positions, thoughts related to antipsychotic medication
and/or behavioral expressions), process (eg, descriptions of what leads to PRN
antipsychotic medication administration), and proximity (eg, in relation to AL/RC
residents and receiving antipsychotic medication, where are roles, attitudes, and process
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situated?). As an extension of coding practices aligned with a grounded theory
approach,160,165 I implemented Adele Clarke’s situational analysis,163,174–176 an approach
that extends earlier theorists’ (eg, Strauss, Corbin, Charmaz) work by incorporating
pragmatic, constructivist and post-modern theories as well as cartographic mapping
concepts. One purpose of situational analysis is to identify many possible interacting
elements and characteristics related to a phenomenon of interest through a systematic
series of visualization exercises, or mapping.163,174 The initial codes facilitated the visual
analytic exercises described below and in the Findings section.
To investigate decision making related to as needed APU from the perspective of
various caregivers within AL/RC settings, I used mapping exercises outlined by Clarke
and her colleagues to extend and describe patterns among the initial codes I
identified.173,175–177 Using analytic memos to reflect on the emergence of topics within the
interviews and potential relationships among these topics, I began with “messy maps”163
for each interview (Figure 1). I used these messy maps to capture the breadth of topics,
elements, and perspectives raised during interviews. Through an iterative process of
analytic memoing I continued to integrate analytic and theoretical relationships, resulting
in numerous maps.
The next phase of Clarke’s situational analysis approach involves developing an
ordered situational map to organize elements identified, during messy mapping, including
those that might be unstated, or “silent.”
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Figure 1. An example of a messy map constructed of interviewee #9

In my case, the goal was to identify elements that illustrate and contextualize the
situation of PRN antipsychotic medication administration within assisted living based not
only on interviews, but also the primary human (eg, residents, staff) and nonhuman (eg,
PRN medications, medication records, order parameters, behaviors) elements involved in
the situation, collective groups or organizations, discourses constructing human and
nonhuman actors, political, sociocultural, temporal, historical, and other pertinent
elements to the situation. Examples and definitions of these components are detailed in
Appendix E.163,174
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Participants described numerous human and nonhuman elements, identified
positions and relationships among these actors and external political and social beliefs,
and expressed varying positions and decision making related to PRN antipsychotic
medication use. I use this ordered map in combination with line-by-line interview coding
to develop themes illustrated in the Findings section. I developed these themes through
intensive analytic memoing and positional maps.163,172,174 Using positions and
relationships among human and nonhuman elements identified by participants, I plotted
these descriptions along axes, using codes and quotes to visualize positions. These
positional maps anchored thematic development and are supported with participants’
quotes.
5.4 Findings
5.4.1 Interview Participants
I sent recruitment emails to 130 facilities from April to June 2021. Nineteen
individuals indicated that they would participate in an interview, 16 consented and
scheduled an interview, and 11 completed an interview. Table 1 describes the
demographic characteristics of the interviewees, who included administrators/executive
directors (n=4), unlicensed direct care workers (n=3), consultant pharmacists (n=2), a
licensed professional nurse (n=1), and a registered nurse/resident care coordinator (n=1).

Table 1. Descriptive characteristics of interview participants.
Characteristics
Age in years
Race/ethnicity

Mean (range) or % (n)
44 (27-64)
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Non-Hispanic White

64% (7)

Asian American or Pacific Islander

18% (2)

Multiracial

9% (1)

Not disclosed

9% (1)

Woman

64% (7)

Man

27% (3)

Gender nonconforming

9% (1)

Gender

5.4.2 Theme 1: Positive, negative, and neutral beliefs and attitudes justify as-needed
antipsychotic medication utilization.
Interview participants described the use of PRN antipsychotic medications, types
of related training, and how a hypothetical utilization threshold (ie, 20% resident
population) at the policy level would affect their work. When answering, participants
conveyed different attitudes and beliefs regarding the use of as-needed antipsychotic
medications in people with dementia living in AL/RC settings. One participant stated that
“medication is an emotional, heavy topic” to discuss. Figure 2 depicts the range of
attitudes expressed by interviews and their relationship with whether to use or not use
antipsychotic medications.
Figure 2. Positional map of expressed ideologies on PRN antipsychotic medication use in
assisted living/residential care residents with dementia.

83

When describing examples of behavioral management and reflecting over the course their
experiences working with residents, participants tended to describe whether it was
appropriate to use or not use PRN antipsychotic medications. Participants underscored
their comments and stories with positive, negative, and/or neutral attitudes regarding the
use of antipsychotic medications.
Nearly every participant iterated in some capacity that medications are effective
when residents exhibit behavioral expressions, pain, and/or other discomfort. Despite all
efforts to address residents’ needs and respond to behavioral expressions, residents may
not respond to nonpharmacologic interventions. Several caregivers shared protocols and
processes that guide behavioral response in the communities where they work. Often,
after a number of unsuccessful nonpharmacologic interventions, they are guided by the
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residents’ care plan and facility policy to escalate to medications as one medication
technician described,
“[We use] at least three interventions usually laid out, like, planned
interventions things that might work: snacks, toileting, repositioning. And
then talking to the family about their [the resident’s] past and getting ideas
to redirect them. […] But if at least three attempts don't work usually for
the course of at least half an hour that's when we would consider giving
them something stronger, some medication.”
Though interview participants with direct care roles were asked to describe
situations where they administered PRN antipsychotic medications to residents, few
shared stories about antipsychotic medications, specifically. In their descriptions of the
effectiveness of medications when working with assisted living, residential care, and
memory care residents, interviewees were inclined to discuss PRN medications overall,
which included other types of medications, “Yeah PRN, so you're talking about
Hydrocodone, Oxycodone, Lorazepam, Morphine, you know?” When asked to describe a
situation that necessitated administration of a PRN antipsychotic medication, nearly
every participant (outside of consultant pharmacists) chose to tell a story about an antianxiety medication administration (eg, lorazepam).
Unlicensed caregivers, registered nurses, and administrators all shared the utility
of medications when working with residents to promote comfort and quality of life. Two
interviewees with nursing credentials (licensed professional nurse and registered nurse)
shared that assisted living and residential care residents with PRN medication orders are
able to self-direct and ask for those medications. However, for residents in memory care
settings,
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“[…] a lot of the residents use antipsychotics and antianxiety
[medications] because it's for their wellbeing and they're up, they’re
functional, they're going to activities, they have a good appetite, they're
socializing, they're interested in things, you know? They’re
communicating to the best of their ability, they’re definitely having a good
quality of life, but if they didn't have those medicines they wouldn't be
having a good quality of life.”
Alternatively, some caregiving staff and those with pharmaceutical backgrounds
stated antipsychotic (and other psychotropic) medications for as-needed use among
residents living with dementia is not appropriate whatsoever. Rather, using these types of
medications functions as a restraint and indicates residents’ needs are not being met. A
consultant pharmacist who works with communities to conduct resident medication
review said,
“These drugs are all indicated to treat schizophrenia and various
psychiatric disorders, but when we're using them to treat dementia, they
don't do anything in dementia, they don't slow its progression. We’re
essentially using a chemical restraint. And sometimes that's necessary
somebody that has exacerbating behaviors and is explosive and hitting
everybody, kicking scratching basically the neuropsychiatric symptoms of
dementia, we don't really have anything to treat those symptoms, so we
default to antipsychotics. You use them basically tranquilizers.”
Overall, despite the job role, interviewees shared that PRN APU has appropriate
and inappropriate uses for assisted living residents. A combination of clinical decision
making, resident-driven care planning, and appropriate staffing were all cited as
facilitators to making an appropriate decision whether to administer PRN antipsychotic
medications or not.
5.4.3 Theme 2: Responding to a resident’s behavioral expression with or without
medication is partially driven by an underlying morality/ethic.
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When participants were asked questions about responding to resident behaviors,
either successfully or unsuccessfully, several individuals raised the premise of
“responding right” or “responding wrong.” Regarding the use of antipsychotic
medications or nonpharmaceutical approaches, participants acknowledged that responses
should ideally center individual residents and their needs. However, respondents
described ethical toggle when deciding to use nonpharmaceutical intervention versus a
PRN antipsychotic medication. This toggle was framed in several ways (Figure 3).
Generally, respondents oriented their perspectives to “medication as a last resort” through
broadly applied nonpharmaceutical interventions or individually designed interventions.
In one community, a medication technician described typical nonpharmaceutical
responses residents’ behavioral expressions:
“We have some residents with dementia and they yell, they scream, so
sometimes they are hungry, we want to offer them snacks, you know?
Maybe their briefs are wet, so we need to change [their briefs]. Or
sometimes there's some resident like to watch TV, so there’s loud music,
you know, some people doesn't want to hear it, so we need to change the,
you know, place. Like, we need to bring [them to] their room, or we need
to bring some things in and turn down the music, you know, like that.”
Some respondents detailed specific interventions that were developed for
individual residents based on specific behaviors. One respondent described a memory
care resident who would often attempt to elope from the secured unit:
“One woman, she ran dog shows, and so, she would travel to different
parts of the country and put on dog shows, and there would be awards, and
all of that, and so, she would believe oftentimes in the afternoons that she
had to get out of here so that she could go catch a plane for a dog show
somewhere. So her care plan listed specific things to say to her, because
she was worried she was going to miss her plane, and so we would say,
‘Oh, my gosh I forgot to tell you it’s been rescheduled until tomorrow.
You’re going to get your flight in the morning.’”
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Figure 3. Positional maps of perceived morality associated with response to assisted
living/residential care residents' behavioral expressions.

Notes. Text in the center box describes the prescribed rule via regulations and
recommended practice.
Other respondents shared that despite all best efforts, sometimes “medications just
work” and one can “try everything” and the resident will remain in distress. The same
respondent above followed the description of the resident who ran dog shows in a
previous life with a caveat and concern for the personal and professional preference
towards nonpharmaceutical interventions, associating too many with negative
consequences,
“So lots of times we use, most times we use, nonpharmaceuticals. My
personal concern is that, having been in long term care since ‘93, I see a
lot of non-licensed staff who are taught to believe that there's a concern
that they're overmedicating people or using those psychotropics for their
convenience. And that bias that is built into them results in them trying too
many non-pharmaceuticals, resulting in poor outcomes for our folks.”
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Interview participants tended to describe multiple perspectives over the course of
their interviews. Nearly every participant started by describing an overarching position
regarding the right or wrong of medications vs. nonpharmacologic interventions.
Concurrently, participants also justified decisions or situations that may be opposite or
contradictory to their primary view.
For example, a consultant pharmacist stating there is no role for PRN
antipsychotic medications and following with a caveat that hospice or end-of-life care
presents an exception to this rule,
“Honestly there's really no role for PRN antipsychotics, there are very rare
circumstances. You know, there's instances, maybe end-of-life care
terminal restlessness. In general, for [PRN] antipsychotics, we call them
low hanging fruit, we need to get rid of those. There's very rare situations
that we should use [them].”

Subtheme 2a: Appropriate vs. inappropriate use of as needed antipsychotic
medications framed by “good guy” vs. “bad guy” mentality. Several participants
indicated they had either worked at settings or heard of settings who abuse PRN
medications. One executive director of a memory care setting shared the complexity
around the issue of as-needed antipsychotic medication use among residents. They said,
“It’s a really touchy subject because I am sure there are some places out
there who overmedicate and they will do that because they don’t want to
deal with the behaviors, which is a huge disservice to our people. So
finding that balance is super important, you know you always hear the bad
guys ruin it for the good guys. That’s true, because a lot of these policies
out there, they don’t allow you to use them as they should be, in the
correct manner, because people abuse it. But we are not all bad I promise
you.”
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Perceptions of goodness also extend to trust in and beliefs about clinical providers
and prescribers responsible for overseeing medication management. A caregiver
speculated on the reasoning behind using medication to respond to behaviors, questioning
whether it is appropriate,
“Since the pill almost seems like a restraint, or I don't want to say a
punishment, but it's like ‘we can't handle you [resident] anymore, so we
need you to take this pill, so we don't have to, you know, deal with you’
is kind of what it feels like. But it can't be that way right? Because there's
all these caring people, the administrator is really nice, the doctor is really
nice, the nurse is really nice.”
One nurse described their perceptions of prescriber’s intentions and knowledge
related to prescribing as-needed antipsychotic medications to residents, suggesting this
treatment modality is both well-intentioned and informed,
“The people who are ordering the medications, I'm assuming they're all
good people and they wouldn't just order things negligently, but I can say
that they are aware enough of the pros and cons of antipsychotics.”
5.4.4 Theme 3: Proximity to medication administration is inversely related to perceived
agency/authority.
Participants discussed the complexity surrounding PRN antipsychotic medication
administration. By the time direct care staff administer a PRN antipsychotic medication
to an assisted living resident, several actors with varying credentials, familiarity, and
proximity to the situation and the resident have made a number of decisions. The
multilayered nature of PRN antipsychotic medication administrations suggests different
power dynamics and ability to participate in the situation (Figure 4). As one participant
shared,
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“It [antipsychotic medication use] is really a prescribers’ issue. The
facility doesn’t write the prescription. So the onus is on the facility to try
to get gradual dose reduction or at least get a response and there's a lot of
physicians that just won't respond. If you ever really wanted to change,
you'd have to mandate some sort of physician training like they had to do
with opioids or something like that. Yeah and probably get the state Board
of Medical Examiner's involved in mandating some sort of specialized
CME [continuing medical education] or something.”
Within the situation of medication administration typically exists the resident
receiving the medication and the staff member administering the medication. Participants
described different levels of agency depending on a) residents’ level of cognitive
impairment and ability to communicate and b) staff’s roles within the settings. One
caregiver described their observations and resulting questions when giving residents with
behaviors medications,
“The pill almost seems like a restraint, or I don't want to say a punishment,
but it's like where we can't handle you anymore, so we need you to take
this pill, so we don't have to deal with you. [...] They give me a pill after [a
resident] does these behaviors and then this is the outcome after [the
resident] takes the pill, just there in [their] chair, you know? So like all the
stuff that’s in my mind as a caregiver, and I don't have the authority to say
anything, or if I did have questions how would I address them or take
them to my administrator or my nurse?”
This participant expressed feeling disempowered to voice their concerns and ask
questions by virtue of their position as an unlicensed direct caregiver. Participants with
medication technician roles tended to focus on the responsibility of medication
administration,
“At night I'm basically the acting supervisor. I make sure that all of the
tasks are done and the caregivers are getting their jobs done as well as
doing whatever scheduled medications there are and PRN medications,
often helping with end of life comfort.”
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Participants also raised the importance of knowing and building relationships with
residents to facilitate quality care and implement best practices. Staff turnover, low
staffing ratios, and low perceived agency among staff within assisted living facilities
compared to external providers were commonly expressed obstacles related to meeting
residents’ needs and responding to behavioral expressions.
Many participants expressed both appreciation and frustration with existing and
proposed regulations and policies. While appreciating the purpose of regulations to
protect the safety and wellbeing of residents as assisted living consumers, participants
feel those in the position to enact rules and requirements are disconnected from the
practice of providing care to residents,
“It is something that you wish, you know, the rule makers in the
legislature and up at DHS [Department of Human Services] knew about
the work that you do when they’re setting regulations. They know they
can't know every building in the whole state of Oregon, but it would be
nice if they would ask for more information about the populations we deal
with and what kind of difficulties we have.”
State regulations set the minimum standards expected of facilities when providing
care and services to residents. Though, rule makers and those in positions to create and
amend these regulations are removed from the daily rhythm within facilities. Though not
explicitly raised in interviews, other service providers external to medication
administration within AL/RC settings (eg, social workers, psychiatric providers) might
have input and agency related to APU.
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Figure 4. Positional map of perceived agency and proximity to PRN antipsychotic
administration in assisted living/residential care settings.

5.5 Discussion
In this study, I explored how those within the AL/RC setting with direct care
connection and medication oversight of AL/RC residents, including direct care staff,
medication aides, administrators, and consultant pharmacists, make decisions regarding
PRN APU. By extending grounded theory practice with a situational analytic approach, I
found that attitudes (ie, positive, negative, and neutral), an underlying morality guiding
nonpharmacologic/pharmaceutical interventions, and perceived agency within the context
of medication administration influence study participants’ ideologies around PRN APU.
These findings highlight the complexity underlying the issue of APU in AL/RC settings
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and build upon narratives of medication management phenomena in the assisted living
context.139,172,200,203
The finding that positive, negative, and even neutral attitudes frame participants’
beliefs around whether to use antipsychotic medications to respond to assisted living
residents’ behaviors is largely confirmatory. Like Kerns and colleagues found in their
studies,29,30,101,283 participants with positive attitudes cited antipsychotic medication use as
largely effective and promote wellbeing, especially for residents living with dementia.
Related to the findings presented by Gill and colleagues,99 participants’ views related to
PRN APU situated along a positive/negative binary. A pattern emerged between job roles
and whether participants were more likely to express positive or negative attitudes
towards APU. At one end of the spectrum, unlicensed caregivers and consultant
pharmacists described how using PRN antipsychotic medication to respond to residents’
behaviors is effectively a chemical restraint for settings with staff that “don’t want to deal
with them [residents].” On the opposite end of the spectrum, medication technicians,
nurses, and administrators were more likely to frame APU as promoting resident quality
of life and wellbeing. Evaluations of the Halting Antipsychotic use in Long-Term care
(HALT) study suggest that staff type plays a role in influencing success or failure of
antipsychotic medication deprescription.286,294 Registered nurses and family members
were described as drivers of represcribing of antipsychotic medications, especially in
response to behaviors labelled as agitation and aggression.286 Combined with the context
of one’s job or role within AL/RC, how participants conceptualize and perceive dementia
and dementia care needs can influence care decisions.295–297
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Dementia care involves systems of thought and belief that guide decisions about
what is “good” and “bad” (ie, morals) and what might be “right” or “wrong” to do (ie,
ethics).298,299 Further, implications of and ethical issues with off-label use of
antipsychotic medications to manage behavioral expressions have been discussed across
the life course and globe.199,300–306 This conversation is further complicated by whether
actors’ motivations align or conflict. An oversimplified example might manifest as
clinicians pursuing therapeutic goals (eg, symptom management), families concern with
safety goals, direct care staff prioritizing resident-centered goals, and administrative staff
might prioritize compliance goals.100,287,298,303,305
Participants’ experiences highlighted an underlying morality that partially drove
whether to approach residents’ behavioral expressions with PRN antipsychotic
medication or nonpharmacologic interventions. Participants detailed examples of when it
is “right” or “wrong” to use either PRN antipsychotic medications or nonpharmacologic
interventions. Based on Oregon Administrative Rules Chapter 411, Division 54, Section
6, when responding to resident behaviors, staff must first attempt nonpharmacologic
interventions and document whether they are effective. If ineffective, and the resident
remains in distress, PRN psychotropic medications may be considered.77,92,122 Major
sources of moral distress for formal caregiving staff include understaffing, perceiving
residents with dementia in pain, not having enough time to provide adequate care.307
Some participants raised concerns with providing care that might be “regulationcentered” as opposed to resident-centered, resulting in unintended consequences.308 Fear
of regulatory noncompliance might lead staff to attempt too many behavioral

95
interventions, prolonging a resident’s pain or distress or putting staff or other resident’s in
harm’s way.31 Participants shared that doing what is best for the resident should drive
decision making, even if what is perceived as “best” includes elements of deception (eg,
white lies).309,310 However, resource constraints and organizational obstacles present
significant barriers to the one-on-one person centered approach that is often required, and
recommended as best practice.13,72,311,312 Other studies have reported similar experiences
across licensed and unlicensed care staff, where organizational and systemic barriers
deprioritize implementation of nonpharmacologic interventions.14,29,313,314
Lastly, participants situated their decision-making within perceived agency and
authority. The human actors that participate in the situation of medication administration
within AL/RC settings vary in proximity (ie, internal vs external) and power within the
situation. In this study, I found an inverse relationship between the perceived authority of
an entity or individual and their proximity to medication administration with AL/RC
settings. At the heart of medication administration within AL/RC are the resident
receiving the medication and the staff person administering the medication. Prior studies
have focused in on the intersection of resident and staff autonomy with regard to
balancing safety, wellbeing, and choice regarding medication management in
AL/RC.139,141,172,203 AL residents have the right to refuse any treatment per resident rights
recognized in regulatory practice,122 but the ability to assert this autonomy is largely
influenced by cognitive capacity, care needs, staff perceptions of residents’ abilities, and
AL/RC setting culture.172,203,290,315,316 Participants remarked on the difference in
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articulating needs and requesting medication by residents living in memory care settings
compared to those in assisted living and residential care.
Long before a medication aide administers a PRN antipsychotic medication to a
resident, other entities outside of the AL/RC setting context have made numerous
decisions, and direct care staff must work within the parameters presented to them.312 In
this study, I found that entities or individuals assigned with the most authority (ie
Department of Human Services rule makers, physicians). Nurses and administrators
oversee the writing of medication order parameters, ensuring direct care staff can
administer medications and treatments without making assessment decisions. Prescribers
write the original orders and generate access to the medications within AL/RC settings.
Pharmacists or nurses review medication orders, recommending changes within the
context of clinical decisions and regulatory compliance. Additionally, residents’ families
present another human element with varying degrees of power over their loved one’s
care, depending on their level of involvement and legal authority (eg, legal guardian,
health proxy). Understanding the scope and context of APU within AL/RC settings
necessitates a broader systems-level approach to this issue— beyond the medication
pass.
5.5.1 Limitations & Future Directions
This study has several limitations worth considering for future research efforts.
First, the ongoing COVID-19 pandemic presented significant barriers to recruitment and
sampling for this study, affecting participant selection into the study. Long-term care
settings, including assisted living, have been disproportionately impacted by both resident
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morbidity and mortality and staffing shortage burdens as a direct result of COVID19.317,318 In addition to this trauma, pandemic-related restrictions limited recruitment and
data collection efforts to fully remote, which adversely affected my ability to build the
trust and relationships necessary with frontline care staff and administrators to gain buyin for this research. Losing the ability to recruit participants onsite required me to rely on
administrators to disseminate information during a period of heightened stress and
burnout.319 Future research teams interested in conducting interviews or focus groups
with the AL/RC workforce should consider investing in strategies that prioritize building
relationships over the long term with administrators and staff and collaborate on data
collection designs that simultaneously mitigate burden and offer an opportunity for
participants to share their experiences.
There were only 11 participants in this study, spread across different facilities and
the state of Oregon. These participants delivered rich, deep interviews, but it is possible
key experiences involving PRN APU are missing based on who had the capacity to
participate and restricting the sample to those with connection to care and medication
oversight within the AL/RC setting. This study would have been greatly strengthened by
interviewing more staff who worked in the same facility and with the same resident
population to aid contextualization of decision making around PRN antipsychotic
medication use. Relatedly, this study only captures the views of direct care staff, nurses,
administrators, and consultant pharmacists. Though participants illustrated connections
and importance of other actors involved in medication administration, resident, family
member, and prescriber perspectives are missing from the narrative presented in this
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study. Future research studies could move upstream and attempt to map out external
mechanisms that influence PRN antipsychotic medication administration, particularly the
relationships and situations that arise among residents, their families, and prescribers.
5.5.2 Conclusions & Implications
This study raises practice and policy implications regarding APU in AL/RC
settings. Roles related to caregiving, ethical considerations, and perceived agency inform
decision making on whether to use antipsychotic medications. Participants described
costs and benefits associated with both PRN APU and nonpharmacologic interventions
when responding to AL/RC residents’ behavioral expressions. Participants’ experiences
emphasize the interactions across multiple levels of care (eg, interpersonal to policy
level). Balancing regulatory goals and norms with resident-centered practices underscores
the need for a systems-level perspective, extending beyond direct care staff passing
antipsychotic medications to residents.
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Appendix B. Recruitment Flyer
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Appendix C. Text from Recruitment Questionnaire and Consent Form for Potential
Interview Participants

Welcome! Thank you for your interest in participating in a research study.
Why is this research being done?
Antipsychotic medication use and administration in AL/RC settings is a public policy
priority in Oregon from a safety, oversight, and quality perspective. Quality Metrics
Council members have raised concerns that the goal of reducing antipsychotic medication
use will result in unintended consequences that may harm individuals with serious mental
illness, or result in residents with behavioral expressions being transferred out of AL/RC
settings.
We are asking you to participate in a research study because of your experience working
with assisted living, residential care, and/or memory care residents. It is important to
learn about your perspectives and experiences. We are looking to interview
administrators, nurses, consultant pharmacists and direct care staff to learn about your
experiences, decision making, and training regarding antipsychotic medication use. This
is not an evaluation of yourself, your staff, or your community.
Please continue to the next page to review additional information about the study and
read the consent form.
Consent to Participate in Research
Download a copy of the following consent form:
https://drive.google.com/file/d/1pHjny1n5nIvdwIbrxviYkrZPipwdmiK/view?usp=sharing
You are being asked to take part in a research study. The bullet points below highlight the
main information about this research for you to consider when deciding whether or not to
join in the study. Please carefully look over the information given to you on this form.
Please ask questions about any of the information you do not understand before you
decide to agree to take part.
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Key Information for You to Consider
● Voluntary Consent. You are being asked to volunteer for a research study. It
is up to you whether you choose to take part or not. There is no penalty if you
choose not to join in or decide to stop your involvement.
● Why is the study being done? The reason for this research is to learn how
and why antipsychotic medications are used in assisted living, residential care,
and memory care populations in Oregon.
● How long will it take? Your participation will take a total of 15 to 30 minutes
over the course of one interview. However, the length of the interview is
dependent on how much information you are willing to share.
● What will I be expected to do? You will be asked to participate in a virtual or
phone interview scheduled at your convenience. The researcher will ask you to
respond to a scenario you might see at work and follow up with a few
questions about how you make decisions and what you do in certain situations.
With your permission, the researcher will record your responses on a recording
device.
● Risks. Some of the possible risks or discomforts of taking part in this study
include breach of confidentiality, becoming upset, tired, frustrated, or
distracted.
● Benefits. You will receive a $20 gift certificate for your participation in this
study. Additionally, the study may help to increase knowledge which may help
others in the future.
● Options. Participation is voluntary and the only alternative is to not
participate.
What happens to the information collected? Information collected for this research
will be summarized in a report that will be shared to stakeholders such as advocacy
organizations, state policymakers, assisted living provider groups as well as published in
academic journals. Any information collected during this study and that can be linked to
you or identify you will be kept private and confidential. No identifiable information,
such as your name or the name of where you work, will be used in any papers or
publications resulting from this study. No information about you will be shared with the
administrator or management here; this study is not an evaluation of your work.
How will I and my information be protected? We will take measures to protect your
privacy including using a codename when referring to you in study materials, and
keeping any materials with identifying information (such as this form) in a password
protected folder that can only be accessed with two-step verification on a virtual private
network at Portland State University. Despite taking steps to protect your privacy, we can
never fully guarantee that your privacy will be protected.
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To protect all your personal information, we will not use your real name when recording
interviews or share any information regarding your participation with the administrator,
supervisors, other staff, or residents. Despite these precautions, we can never fully
guarantee that all your study information will not be revealed.
Individuals and organizations that conduct or monitor this research may be permitted
access to inspect research records. This may include private information. These
individuals and organizations include the Institutional Review Board that reviewed this
research and Dr. Paula Carder, the director of the Institute on Aging at Portland State
University.
What if I want to stop my part in this research? Your part in this study is voluntary.
You do not have to take part in this study, but if you do, you may stop at any time. You
have the right to choose not to take part in any study activity or completely stop at any
point without penalty or loss of benefits to which you are otherwise entitled. Your
decision whether or not to join in will not affect receiving the gift card, or your
relationship with the researchers or Portland State University.
Will it cost me money to take part in this research? There is no cost to taking part in
this research, beyond your time.
Will I be paid for being in this research? You will receive a $20 gift card for
participating in this research.
Who can answer my questions about this research? If you have questions, concerns,
contact the research team at:
Sarah Dys, MPA

978-606-1033

sdys@pdx.edu

Paula Carder, PhD

503-725-5144

carderp@pdx.edu

Who can I speak to about my rights as a part of research? The Portland State
University Institutional Review Board (“IRB”) is overseeing this research. The IRB is a
group of people who independently review research studies to ensure the rights and
welfare of participants are protected. The Office of Research Integrity is the office at
Portland State University that supports the IRB. If you have questions about your rights,
or wish to speak with someone other than the research team, you may contact:

Office of Research Integrity

Phone: (503) 725-5484

PO Box 751

Toll Free: 1 (877) 480-4400

Portland, OR 97207-0751

Email: psuirb@pdx.edu
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Consent Statement
I have had the chance to read and think about the information in this form. I have asked
any questions I have, and I can make a decision about my participation. I understand that
I can ask additional questions anytime while I take part in the research.
Please state one of the following:
□ I agree to take part in this study
□ I do not agree to take part in this study
•
•

If participant consents, move to next section.
If participant does not consent, move to end of form.

1. What is the name of the assisted living, residential care, or memory care
community where you work? If you work at more than one community, please
indicate how many communities you work for.
2. How many hours do you work on a typical week?
3. What is your current position job title?
a. Direct care staff- No health license or certification
b. Direct care staff- Certified Medication Aide/Technician
c. Direct care staff- Certified Nursing Assistant
d. Licensed vocational/professional nurse (LPN/LVN)
e. Registered nurse (RN)
f. Resident Care Coordinator/Health and Wellness Director
g. Pharmacist/Consultant Pharmacist
h. Administrator/Executive Director
i. Other: ________________________
4. What is your age?
5. Which race/ethnicity/ities do you identify as? Please select all that apply.
a. African American/Black
b. American Indian/Native American/Alaska Native
c. Asian/Asian American/South Asian
d. Hispanic/Latinx
e. Native Hawaiian or Pacific Islander
f. White
g. Other: ________________________
h. Prefer not to say
6. How do you identify?
a. Woman
b. Man
c. Transgender woman
d. Transgender man
e. Nonbinary
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f. Gender non-conforming
g. Other: ________________________
h. Prefer not to say
Please use the following link to schedule your interview.
https://calendly.com/sdys/antipsychotic-use-in-oregon-assisted-living
We will use the email address you provide here to send you your $20 Amazon gift
certificate.

End of Form.
Thank you so much for your time and participation! I look forward to speaking with and
learning from you!
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Appendix D. Interview guide
Introduction: Older adults living with Alzheimer’s disease and related dementias are
more likely to express certain behaviors. When living in an assisted living or residential
care environment, it is often up to caregiving staff to respond to resident’s behaviors. You
may be aware that antipsychotic medication use and administration in AL/RC settings is
a public policy priority in Oregon from a safety, oversight, and quality perspective.
There is a lot of talk about antipsychotic medications, but we would like to know more
about your experiences working with older adults in assisted living.
Can you start by telling me a little bit about your job and what your responsibilities are?
1. Thinking about residents who have lived in this community who express
behaviors, can you tell me about a time when one of those residents was helped
through successful management by you and other staff?
2. How about a resident whose behavioral expressions were so severe that you or
your staff were not able to respond, can you tell me that story?
FOLLOW UP QUESTION BANK
• How do you know if an intervention works or does not work when responding to
residents’ agitation, anxiety, or distress?
•

What types of training have you had on medication administration in older adults?

•

Please describe a situation when you administered a PRN antipsychotic
medication.

•

How did you decide to administer this antipsychotic medication? Was there
anything you would have done differently?

•

What procedures or protocols does your facility/community/company have on
record for the use of antipsychotic medications?

•

If a resident has an order for an antipsychotic medication, what are you looking
for when reviewing their Medication Administration Record (MAR)?

•

How has the COVID-19 pandemic affected medication administration at this
community?

•

Let’s imagine the state proposes a rule that no more than 20% of residents can
have an as needed antipsychotic medication. How would that affect your work?
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Appendix E. Ordered situational map of participant interviews
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Chapter 6: Synthesis of Research
This dissertation investigated how and why antipsychotic medications are used in
AL/RC settings, focusing in on the Oregon policy and practice landscape. Through
specific aims, I explored the following research questions:
1) What is the scope of psychotropic medication-related survey deficiency citations

in Oregon AL/RC settings;
2) Are organizational characteristics of AL/RC settings associated with antipsychotic

use prevalence?; and
3) How do care AL/RC staff make decisions about antipsychotic medication

administration in Oregon AL/RC settings?
I designed this study with the intention of bringing together multiple data sources,
perspectives, and methods to comprehensively describe the situation of APU within
Oregon’s AL/RC population. The perspectives reflected in this study in regulatory
oversight, AL/RC resident population within the state, and experiences of a selection of
care staff and providers who have a role in providing care or overseeing medication
management in AL/RC.
6.1 Main Takeaways
Across the three studies undertaken in this dissertation, I found a combination of
confirmatory evidence as well as novel contributions to the empirical discussion of APU
in older adults living with ADRD and in AL/RC settings. In the section, I summarize the
main findings across the three research studies.

110
In Chapter 3, I analyzed narrative descriptions of deficiency citations issued to
licensed AL/RC settings in Oregon from 2015 to 2019. Specifically, I analyzed citations
issued for noncompliance with Oregon Administrative Rule 411-054-055-06,
Psychotropic Medication. Similar to other studies,194,196 I found that most deficiencies
were issued because of errors with documentation. The difference in severity between
recordkeeping errors and abuse (ie, chemically restraining residents) is important to
consider in combination with the relatively low prevalence of psychotropic medications
issued (170 over a four-year period). However, documentation discrepancies or missing
information does have implications for care provision. Lack of documenting
implementation and effectiveness of nonpharmacologic interventions and how individual
residents express their behaviors was compounded by lack of role clarity and specificity
of medication administration parameters. Additionally, it is unclear based on the data
included for this study how AL/RC settings implement plans for correction and the types
of assistance provided by the DHS/APD to facilitate improvement. These findings raise
questions regarding the balance, or lack thereof, between regulatory expectations and the
practicalities of caregiving and operating an AL/RC setting.
Chapter 4 offers a state-level perspective on APU within Oregon’s AL/RC
population. Other studies examining factors associated with rates of APU are conducted
at the individual-level with access to residents’ medication administration records and/or
electronic health records.16,127,132,133,231,280,281 In prior work, we found that AL/RC
residents living in MC units, who had a serious mental illness or diagnosed with ADRD
were more likely to receive an antipsychotic medication in the prior 7-day period.134
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However, patterns of association seen among individual AL/RC residents might not be
replicated when comparing settings of AL/RC residents.320,321 Assuming that higher
proportions of residents with ADRD or serious mental illness will show a similar
magnitude of effect on the rate of APU within AL/RC settings is an individualistic
fallacy.322,323 One conclusion in line with this fallacy might look like the following: to
lower the rate of APU in AL/RC settings in Oregon, we must reduce the proportion of
residents with ADRD or serious mental illness in any given AL/RC setting.
The findings demonstrated in Chapter 4 indicate that at the setting-level
organizational characteristics are associated with larger effects on higher or lower APU
rates among AL/RC settings. In particular, AL/RC settings with a very high prevalence of
Medicaid users (67.8%–100%) reported average APU rates nine percentage points higher
than AL/RC settings with low Medicaid use (0%–15%). Our analysis of individual
residents did not find a significant relationship among individual residents’ Medicaid
status and APU.134 This suggests that APU at the setting-level is partially affected by an
organization’s resource capacity—having a higher proportion of residents using Medicaid
reimbursement to pay for services compared to private pay has been associated with
higher rates of APU.256,259,265
Lastly, Chapter 5 takes dives into the experiences and positions of those providing
care to and overseeing medications for AL/RC residents, including unlicensed caregivers
and medication aides, nurses, administrators/executive directors, and consultant
pharmacists. Using in-depth, semi-structured interviews, I explored participants’
experiences with responding to residents’ behavioral expressions, administering PRN
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antipsychotic medications, and thoughts on a hypothetical policy related to limiting PRN
APU. Through situational analysis, I used mapping techniques to elicit patterns and
themes within the narrative data.176 I found that individual perceptions and attitudes,
ethics of care, and perceived agency related to APU influence participants’ ideologies
and decisions to use pharmaceutical or nonpharmacologic approaches to behavior
response.
For interpretive ease, the various positions described in Chapter 5 are visualized
along two-dimensional axes. This oversimplification might suggest participants’
positionality, experiences, and approaches fall explicitly along binary spectrums. In
reality, participants shared multiple perspectives over the course of their interviews.
Every participant expressed how deciding whether to use a PRN antipsychotic
medication relied on numerous factors, situations, and contexts for each individual
resident. This individualization is one of the values underpinning the AL/RC model,324
and has been demonstrated in the context of health care needs.153,154 However, AL/RC
values, regulatory oversight, and resident-centeredness might not align cohesively in
practice.325 Regarding PRN APU in Oregon AL/RC residents, providers and caregivers
are forced to simultaneously balance and prioritize regulatory goals, organizational
constraints, and complex care provision resulting in a multilayered, difficult, and unique
situation.
6.2 Social World of Antipsychotic Medication Use in AL/RC
I operationalize elements of the Institutional Analysis and Development
framework36,150 by using situational analysis163 to contextualize the findings of the three
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studies undertaken in this dissertation. The elements of the framework described in
section 2.7 informed the initial study design and approach to this dissertation study.
These included exogenous variables such as material conditions (eg, organizational and
environmental characteristics), community characteristics (eg, Oregon AL/RC resident
population characteristics), and rules (eg, Oregon Administrative Rules Chapter 411,
Division 54, training requirements, compliance guidelines).
I focused on the operational level of analysis, or the action situation,150 in this
dissertation. Figure 1 presents the social world of APU in Oregon AL/RC settings
through the lens of the dissertation findings. I recognize it is not possible to
comprehensively cover every possible action and outcome that may occur. Social world
maps embrace the inherent “messiness” of complex situations, highlighting the
possibilities for actions and decisions across relevant elements, such as human actors,
nonhuman elements, discourses, and sociopolitical elements).163,174,177,326
Across the entire situation of APU in Oregon AL/RC settings, I present major
actors’ subworlds,169,170 in interconnected circles: residents, families, AL/RC staff,
consultant pharmacists, primary care providers, regulatory entities (state and federal),
pharmaceutical industry, and long-term care research. APU in AL/RC populations is the
intersection of health policy, practice, and research. The focused attention on off-label
antipsychotic medications in older adults living with ADRD was birthed in the realm of
research and manifested through policy decisions (ie black box warning, quality
metrics).19,20,93–95

Figure 1. Social world of antipsychotic medication use in Oregon's assisted living/residential care settings.
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Actors within these different worlds occupy different positions within and
external to the AL/RC setting. These positions are associated with different levels of
power and agency as it relates to access to antipsychotic medications (through
prescriptions), parameters for use (through medication orders), and interpretations of
scenarios that might result in the use of an antipsychotic medication (eg, residents’
persistent agitation).
Reflecting on APU described across this dissertation, the regulatory elements
associated with antipsychotics use in AL/RC settings in Oregon are reflected in
administrative rules, which govern licensing of AL/RC settings. These regulations
intervene on the organizational level, the AL/RC setting. These rules specify actions that
staff must take regarding psychotropic medication use generally (encompassing
antipsychotic medications in addition to other classes) as well as documentation
requirements and a stipulation that prioritizes nonpharmacologic attempts at intervention
when responding to residents’ behavioral expressions or working with PRN psychotropic
medication orders.
Oregon Administrative Rules intervene on staff actions, understandably because
these rules govern what happens within the AL/RC setting. However, as demonstrated in
this dissertation, there are factors upstream of direct care staff passing medications
directly related to the use of antipsychotic medications. These study findings indicate an
imbalance between power and proximity to the situation of medication situation, where
those with the power to facilitate access to antipsychotic medications (ie, prescribers) are
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not the ones penalized through fines and citations for administrations that occur by those
with less agency in the situation (ie, unlicensed caregivers). Creative solutions that reflect
the practical reality of providing care in AL/RC settings are sorely needed, given the
extant literature regarding the substantial risks associated with the use of antipsychotic
medications in older adults living with dementia16,22,232,281,327 the ethics of care in assisted
living,298,328 and implications for AL/RC resident quality of life.68,230,236,237,329–332
6.3 Strengths
One of the main strengths of this dissertation study is that it embraces the complexity
and contextual nature of antipsychotic medication administration and decision making in
AL/RC settings. This study used three sources of data to inform the current narrative
around APU in Oregon’s AL/RC populations: administrative records from Oregon
DHS/APD, secondary data from a state-wide survey of AL/RC settings, and primary data
collected using qualitative methods and incorporating multiple perspectives. Most
research of APU in older adults living with dementia is conducted in NH populations. To
inform policy and practice improvements, having population and context-specific
evidence is critical. This study contextualizes the situation of APU in AL/RC settings
within Oregon’s licensing and practice context.
Another strength of this study was the formation of a stakeholder advisory board.
Especially during study design, AL/RC providers, business owners, clinical practitioners,
and those with experience working and making a career out of AL/RC practice provided
guidance, recommendations, and feedback. Over the course of the study period, I was in
touch with stakeholders over email, offering periodic updates and opportunities to
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provide written and verbal reactions to my initial findings. These Oregon-based
practitioners provided invaluable insights and reactions that helped this study take shape.
Another strength of this dissertation study is the opportunity to contribute to a small
but growing literature base that centers on the minutiae of AL/RC populations, policies,
and practices. Assisted living researchers are placed in a paradox: advocating that AL/RC
settings and NH settings are not the same, yet heavily relying on NH literature to frame
and justify research questions and study design. In this dissertation, I lean a robust array
of studies taking place in NH contexts, while a main argument of this study is that the
AL/RC context is specific and unique, particularly in Oregon. Given the growing share of
AL/RC settings as a long-term care option,54,119 it is increasingly crucial to collect data
and design studies that account for AL/RC populations and settings.
Further, this study adds nuance to the empirical and practical discussion of APU in
AL/RC settings. Much of the existing literature documents the prevalence of APU,
associations with individual and organizational factors, and perceptions of using these
medications in older adults, but in silo. Through situational analysis, I draw together and
contextualize diverse data sources and perspectives that attempts to conceptualize the
situation of APU in Oregon’s AL/RC settings holistically.
6.4 Limitations and Future Directions
There are also several limitations of this study to consider. A significant limitation is
that this study misses a central perspective related to AL/RC settings and APU: residents.
Though each of the three studies addresses AL/RC residents tangentially, not one centers
their voices or perspectives. This dissertation would be greatly strengthened by including
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residents’ perspectives on medication management and the experiences of residents living
in memory care and their relationships with staff and external care providers, similar to
the work undertaken by Kemp and colleagues,153 Another limitation was the remote
nature of performing this study. Lacking observational elements and fully utilizing
myself as a research instrument in the field impacted my ability to fully conduct a
situational analysis. Further, conducting this dissertation during COVID-19 pandemic
that disproportionately affected congregate care settings has ethical implications. Though
an important area of study, it is possible that pursuing primary data collection in the midst
of a global pandemic introduced additional stress and burden to AL/RC providers and
staff.
Though the in-depth interviews conducted in Chapter 5 portrayed rich narratives from
the perspective of AL/RC staff, quantitative measures of staffing levels are missing.
Having a sufficient number of staff to meet residents’ needs is at the crux of upstream
intervention to reduce the use of antipsychotic use among AL/RC residents living with
ADRD. 297,312,314 Oregon does not currently mandate minimum staffing ratios in AL/RC
settings, though instituting minimum staffing standards in MC settings is under
consideration in the state legislature.333 Recent AL/RC findings suggest that direct care
staffing policies are associated with positive health outcomes and health services
utilization.334 A future study could build on this work to identify staffing models and
practices associated with appropriate APU.
Regarding data used in this study, it is worth considering whether the measures and
analytic design adequately contextualize APU. The deficiency citation data did not
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contain the level of detail I had expected regarding the scope of the deficiency. I was
limited to what the surveyor chose to document in their report and what was publicly
available. Future research could incorporate interviews with surveyors, facility staff, and
residents to contextualize and improve understanding of quantitative and qualitative
findings related to deficiency citations and conceptualizations of quality and safety in
long-term care. Additionally, if feasible, an extension of this situational analysis could
include a shadowing study of the survey process where a researcher follows along a
survey team, observes the licensing survey, and sits on the debrief and issuing of citations
to capture how regulatory expectations and practical realities are weighed against each
other.
Finally, the purpose of this study was to contribute to the AL/RC-specific evidence
base, specifically in Oregon. Though it is possible to glean many lessons from the studies
presented in this dissertation, the state-specific nature of the work has implications for
generalizability to other states or AL/RC contexts around the globe. The findings
presented in this study should be considered within their context. It is promising that
many of the findings across each of the studies reflect similar findings reported in other
NH and AL/RC literature. However, the findings here are discussed with the explicit
purpose of informing the situation of APU within Oregon AL/RC contexts and should be
interpreted as such.
6.5 Conclusion: Public Health Significance
This dissertation study focuses in depth on one particular situation: APU among
older adults who happen to live in AL/RC settings. The specific situation of antipsychotic
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medication use in AL/RC settings has broader, public health implications to consider.
Broadly, this study has public health implications related to demography, systems
thinking, population health, and the future of our society.
The oldest-old in the United States population (85 years and older) are the fastest
growing segment of the population.42 Most older adults will live at home in their
communities until end-of-life. However, an increasing number of adults will need longterm services and supports or some form of paid caregiving at some point in their lives.50
Additionally, Alzheimer’s disease, the sixth leading cause of death in the U.S. is
increasing in prevalence. By 2050, an estimated 13 million adults over the age of 65 will
be living with Alzheimer’s disease.44 Alzheimer’s disease and other dementias are
terminal conditions, with no cure. Dementia symptoms largely include behavioral
expressions, which can be a form of communication, articulation of pain or unmet needs,
and range in severity.3,130 The increasing prevalence of older adults, and older adults
living with ADRD suggest an increase for long-term care settings, including AL/RC.
If the population of people living with dementia and expressing behaviors
continues to increase, with no current curative measures, it is past time to re-think what
caring for and supporting those with these conditions means. This shift in population
demography, increase in dementia prevalence, and nature of social and health service
provision necessitates a systems level framing. Systems thinking reflects a public health
vision that impacts everyone living in the U.S. AL/RC settings present the intersection of
healthcare, housing, social services, and quality of life.
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The appropriateness of pharmaceutical or nonpharmacologic response to
behavioral expressions in dementia is, in part, a sociocultural question. APU is often
discussed in the realm of individual residents and their needs, but policy solutions target
population level interventions. Understanding the appropriate characteristics associated
with higher or lower rates of APU can provide insight into policy development and
design of appropriate intervening mechanisms. A multilevel perspective offers
opportunities for a multipronged approach to improving rates of potentially inappropriate
medication use and overall quality of life for older adults living in AL/RC settings. Public
health, specifically population health, offers a path forward to promote and work towards
a more equitable world across the life course and for those with varying physician and
cognitive abilities.
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